RayKnowChina Research Map
Shortlist0

BeijingPeking Union Medical College / Chinese Academy of Medical Sciences

Peking Union Medical College Hospital

北京协和医院

Listed for 42 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Peking Union Medical College Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led1 open trial led
  3. Hepatocellular carcinoma肝细胞癌65 papers led10 open trials led
  4. Stomach cancer胃癌54 papers led
  5. Retinoblastoma视网膜母细胞瘤0 papers led
  6. Osteosarcoma骨肉瘤4 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤6 papers led
  8. Neuroblastoma神经母细胞瘤7 papers led1 open trial led
  9. Ewing sarcoma尤文肉瘤1 paper led
  10. Multiple myeloma多发性骨髓瘤27 papers led2 open trials led
  11. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病1 paper led
  12. Aplastic anaemia再生障碍性贫血16 papers led1 open trial led
  13. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症7 papers led
  14. Beta thalassaemiaβ 地中海贫血1 paper led
  15. Haemophilia A血友病 A17 papers led
  16. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  17. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  18. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病8 papers led
  19. IgG4-related diseaseIgG4相关性疾病47 papers led7 open trials led
  20. Myasthenia gravis重症肌无力6 papers led
  21. Moyamoya disease烟雾病9 papers led
  22. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎3 papers led
  23. Takayasu arteritis大动脉炎27 papers led
  24. Hepatic echinococcosis肝包虫病0 papers led
  25. Idiopathic pulmonary fibrosis特发性肺纤维化18 papers led
  26. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病14 papers led
  27. Amyotrophic lateral sclerosis肌萎缩侧索硬化症44 papers led
  28. Spinal muscular atrophy脊髓性肌萎缩症3 papers led1 open trial led
  29. Fabry disease法布雷病2 papers led
  30. Pompe disease庞贝病1 paper led
  31. Duchenne muscular dystrophy杜氏肌营养不良2 papers led
  32. Behçet disease白塞病49 papers led2 open trials led
  33. IgA nephropathyIgA 肾病5 papers led
  34. Gaucher disease戈谢病1 paper led
  35. Osteogenesis imperfecta成骨不全症14 papers led
  36. Primary biliary cholangitis原发性胆汁性胆管炎22 papers led1 open trial led
  37. Primary sclerosing cholangitis原发性硬化性胆管炎3 papers led
  38. Congenital diaphragmatic hernia先天性膈疝2 papers led
  39. Hirschsprung disease先天性巨结肠1 paper led
  40. Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
  41. Hereditary angioedema遗传性血管性水肿10 papers led
  42. Majeed syndromeMajeed 综合征0 papers led

Not listed for: Hepatoblastoma, Chordoma, Fanconi anaemia, Wilson disease, Biliary atresia, Alport syndrome, Niemann–Pick disease type C, Familial adenomatous polyposis, Leber hereditary optic neuropathy, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

5 hospitals in Beijing for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueEBV & screeningInduction / concurrent chemotherapy
Departments in papersRadiation oncologyENT / head & neck surgeryPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 002025

13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2/Phase 3
    Started
    2024-01
    Registry
    NCT06907602

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryImmunotherapyNeoadjuvant & combined treatment
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncology
Papers it led4
  1. Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study.2024Frontiers in immunologyFree full text
  2. The clinical outcomes of endoscopic submucosal dissection for superficial circumferential esophageal squamous cell carcinoma may be not as ideal as expected.2023Gastrointestinal endoscopy
  3. Application of intraoperative nerve monitoring for recurrent laryngeal nerves in minimally invasive McKeown esophagectomy.2022Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusFree full text
  4. Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients.2022Postgraduate medical journal
All its trials on ClinicalTrials.gov, any status12
  1. Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06907602Lead sponsorPhase 2/Phase 3Start 2024-01
  2. A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT05636150Lead sponsorPhase 2Start 2022-03
  3. The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.Status unknownNCT05170542Lead sponsorPhase 2Start 2021-12
  4. Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT05302011Lead sponsorPhase 2Start 2020-06
  5. Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell CarcinomaCompletedNCT04568200Lead sponsorPhase 2Start 2020-06
  6. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  7. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  8. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  9. A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in ChinaCompletedNCT03565003Study sitePhase 1/Phase 2Start 2018-11
  10. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  11. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Study sitePhase 2Start 2016-01
  12. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
More papers found outside PubMed (not counted)11
  1. A multi-epitope mRNA vaccine for effective immunotherapy in esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyarticle
  2. Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.2025Journal of Clinical Oncologyarticle
  3. The number of lymph node dissections related to survival of patients with locally advanced esophageal squamous cell carcinoma after neoadjuvant therapy: A single-center study.2025Journal of Clinical Oncologyarticle
  4. A phase 2 study of fruquintinib in combination with S-1 for second-line treatment of esophageal squamous cell carcinoma after first-line immunotherapy failure.2024Journal of Clinical Oncologyconference-abstract
  5. A prospective phase 2 single-arm study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (Keypoint-1).2024Journal of Clinical Oncologyconference-abstract
  6. Abstract CT274: BGB-A317-LBL-007-202: A phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as firs2024Cancer Researchconference-abstract
  7. 203P Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)2023Annals of Oncologyarticle
  8. Neoadjuvant tislelizumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis of a phase 2 study.2023Journal of Clinical Oncologyconference-abstract
  9. Neoadjuvant pembrolizumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim results.2022Journal of Clinical Oncologyconference-abstract
  10. A Novel Potential Diagnostic and Prognostic Biomarker for Esophageal Cancer2021Research Squarepreprint
  11. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 65 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
65
2021–2025
Trials led
26
any status, ClinicalTrials.gov
Open trials led
10
recruiting or about to
Open trials as a site
9
led by another institution
Papers led per year
2021: 141420212022: 151520222023: 181820232024: 101020242025: 772025

17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 19

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Registry
    NCT07590336

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  2. Recruiting
    Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07639138

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  3. Recruiting
    Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07014150

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  4. Recruiting
    ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT07157969

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  5. Recruiting
    β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07317414

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College Hospital; 2 listed hospitals as study sitesBeijing, Nanjing, Xuzhou

  6. Recruiting
    Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT07832006

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  7. Recruiting
    Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06215651

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  8. Recruiting
    Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06363006

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  9. Recruiting
    An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT07101237

    Age 18 years to 70 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  10. Not yet recruiting
    Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06041490

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  11. Recruiting
    MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07479485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Tianjin, Zhengzhou

  12. Recruiting
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06954467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou

  13. Recruiting
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07170345

    Age 18 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai

  14. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  15. Recruiting
    NWRD06 DNA Plasmid for HCC After Curative Resection.
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07324304

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Harbin

  16. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  17. Recruiting
    To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07594964

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  18. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  19. Not yet recruiting
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-12
    Registry
    NCT07866612

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersRadiology / nuclear medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine
Papers it led65
  1. Genetic Adaptation to Tibetan High Altitude and Hepatocellular Cancer Risk: Integrative Bidirectional Mendelian Randomization and Single-Cell RNA Sequencing Analysis.2026High altitude medicine & biology
  2. Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma.2025Cancer immunology, immunotherapy : CIIFree full text
  3. RAD54L Is a Prognostic Biomarker and Demonstrate Correlation With Drug Sensitivity in Hepatocellular Carcinoma.2025Cell biology international
  4. Lung cancer associated transcript 1 binds heat shock protein 90 to promote growth of hepatocellular carcinoma.2025Cellular signalling
  5. Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial.2025GutFree full text
  6. PAFAH1B3 Exists in Linear Chromosomal and Extrachromosomal Circular DNA and Promotes HCC Progression via EMT.2025International journal of molecular sciencesFree full text
  7. FAD synthase confers ferroptosis resistance and restrains CD8+ T cell recruitment in hepatocellular carcinoma.2025Nature communicationsFree full text
  8. A Multi-phase CT Dataset for Automated Differential Diagnosis of Liver Tumors.2025Scientific dataFree full text
  9. MR Imaging Features for Predicting Microvascular Invasion of Hepatocellular Carcinoma: Is Radiomics Truly Helpful?2024Academic radiology
  10. Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting.2024Clinical and molecular hepatologyFree full text
  11. Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  12. HCCDB v2.0: Decompose Expression Variations by Single-cell RNA-seq and Spatial Transcriptomics in HCC.2024Genomics, proteomics & bioinformaticsFree full text
  13. Research trends of cellular immunotherapy for primary liver cancer: A bibliometric analysis.2024Human vaccines & immunotherapeuticsFree full text
  14. Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.2024International journal of radiation oncology, biology, physics
  15. POSTN+ cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma.2024Journal for immunotherapy of cancerFree full text
  16. Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma.2024Journal for immunotherapy of cancerFree full text
  17. Radiomics as a tool for prognostic prediction in transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.2024La Radiologia medicaFree full text
  18. Liver fibrosis as a predictor of liver failure and outcome following ALPPS among patients with primary liver cancer.2024Scientific reportsFree full text
  19. Development and validation of a selenium metabolism regulators associated prognostic model for hepatocellular carcinoma.2023BMC cancerFree full text
  20. Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards.2023Biochimica et biophysica acta. Reviews on cancer
  21. CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus.2023European radiology
  22. Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination.2023Expert review of vaccines
  23. Integrated analysis revealing a novel stemness-metabolism-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  24. Case Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor: 2023Frontiers in immunologyFree full text
  25. Letter to the editor: Successful treatment of multidrug-resistant hepatis C after >12 months of continuous therapy with direct-acting antivirals.2023Hepatology (Baltimore, Md.)
  26. Letter to the Editor: Several issues to consider in the study of hepatocellular carcinoma progression mechanism.2023Hepatology (Baltimore, Md.)
  27. Letter to the Editor: Some reflection on the research related to METTL1 promoting radiotherapy resistance in hepatocellular carcinoma.2023Hepatology (Baltimore, Md.)
  28. Letter to the Editor: Is eliminating METTL1-mediated accumulation of PMN-MDSCs sufficient to prevent hepatocellular carcinoma recurrence after radiofrequency ablation?2023Hepatology (Baltimore, Md.)
  29. Letter to the editor: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage HCC.2023Hepatology (Baltimore, Md.)
  30. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.2023Hepatology internationalFree full text
  31. An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  32. The mesenchymal circulating tumor cells as biomarker for prognosis prediction and supervision in hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  33. Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib.2023Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  34. Classification of metastatic hepatic carcinoma and hepatocellular carcinoma lesions using contrast-enhanced CT based on EI-CNNet.2023Medical physics
  35. B4GALNT1 promotes carcinogenesis by regulating epithelial-mesenchymal transition in hepatocellular carcinoma based on pan-cancer analysis.2023The journal of gene medicine
  36. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.2023World journal of gastroenterologyFree full text
  37. Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing.2022Annals of hepatology
  38. A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma.2022BMC cancerFree full text
  39. Key Genes Associated with Tumor-Infiltrating Non-regulatory CD4- and CD8-Positive T Cells in Microenvironment of Hepatocellular Carcinoma.2022Biochemical geneticsFree full text
  40. Letter to the editor: Liver transarterial chemoembolization plus sunitinib for unresectable hepatocellular carcinoma.2022Clinics and research in hepatology and gastroenterology
  41. MRI-based radiomics distinguish different pathological types of hepatocellular carcinoma.2022Computers in biology and medicine
  42. Letter to editor: How to select eligible hepatocellular carcinoma patients with portal vein tumor thrombus for deceased donor liver transplantation?2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  43. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  44. Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors.2022Frontiers of medicine
  45. An MMP-based risk score strongly distinguishes prognosis in hepatocellular carcinoma after resection.2022Future oncology (London, England)
  46. Diagnostic and prognostic potential of methylated septin 9 needs more evidence in hepatocellular carcinoma.2022HPB : the official journal of the International Hepato Pancreato Biliary Association
  47. Research progress and prospects of circulating tumor cells in hepatocellular carcinoma.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  48. Letter to the editor: Cautious use of multistate modeling in prognosis analysis of HCC.2022Hepatology (Baltimore, Md.)
  49. Letter to the Editor: Inflammation influences the prognosis of hepatocellular carcinoma.2022International journal of clinical oncology
  50. HBsAg seroclearance reduces the risk of late recurrence in HBV-related HCC.2022Journal of hepatology
  51. Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study.2022World journal of gastroenterologyFree full text
  52. Dynamic 18F-FDG PET imaging of liver lesions: evaluation of a two-tissue compartment model with dual blood input function.2021BMC medical imagingFree full text
  53. Three-dimensional bio-printing of primary human hepatocellular carcinoma for personalized medicine.2021Biomaterials
  54. Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma.2021Cancer immunology, immunotherapy : CIIFree full text
  55. An ectopic adrenocortical oncocytic adenoma in the liver highly mimicking hepatocellular carcinoma: case report and literature review.2021Diagnostic pathologyFree full text
  56. Acute exacerbation of asthma induced by combined therapy of programmed death-1 Blocker plus lenvatinib in a patient with advanced hepatocellular carcinoma.2021European journal of cancer (Oxford, England : 1990)
  57. Fasciitis induced by sintilimab in a patient with recurrent hepatocellular carcinoma.2021European journal of cancer (Oxford, England : 1990)
  58. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study.2021European journal of nuclear medicine and molecular imaging
  59. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules.2021European journal of nuclear medicine and molecular imaging
  60. Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma.2021Frontiers in immunologyFree full text
  61. Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients.2021International immunopharmacology
  62. Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data.2021JAMA oncology
  63. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.2021Journal for immunotherapy of cancerFree full text
  64. Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease.2021Journal of hepatology
  65. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma.2021World journal of gastroenterologyFree full text
Chinese-language papers (not in the count)1
  1. [The value of autoantibodies in the diagnosis and prognosis of liver cancer].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status48
  1. 68Ga-NYM207 PET/CT Imaging in Hepatocellular CarcinomaRecruitingNCT07590336Lead sponsorPhase 1/Phase 2Start 2026-06
  2. β-alanine in the Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT07317414Lead sponsorPhase 2Start 2025-12
  3. ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCCRecruitingNCT07157969Lead sponsorPhase 2Start 2025-02
  4. Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular CarcinomaRecruitingNCT07014150Lead sponsorPhase 2Start 2025-06
  5. Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular CarcinomaRecruitingNCT06215651Lead sponsorPhase 2Start 2024-03
  6. Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular CancerRecruitingNCT06363006Lead sponsorPhase 1Start 2024-03
  7. An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.RecruitingNCT07101237Lead sponsorStart 2024-08
  8. Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver TransplantationNot yet recruitingNCT06041490Lead sponsorPhase 2Start 2023-09
  9. Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor MicroenvironmentActive, not recruitingNCT07437859Lead sponsorStart 2025-10
  10. A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT05981066Lead sponsorN/AStart 2023-07
  11. Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCCStatus unknownNCT05842317Lead sponsorPhase 1/Phase 2Start 2022-09
  12. Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT05536427Lead sponsorPhase 1Start 2022-10
  13. Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCCStatus unknownNCT05339321Lead sponsorPhase 1Start 2021-04
  14. Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular CarcinomaStatus unknownNCT05048017Lead sponsorPhase 2Start 2021-10
  15. Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular CarcinomaStatus unknownNCT05161143Lead sponsorPhase 2Start 2021-12
  16. Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B PopulationActive, not recruitingNCT06379334Lead sponsorStart 2020-12
  17. Lenvatinib Combined Toripalimab in Advanced Hepatocellular CarcinomaStatus unknownNCT04368078Lead sponsorPhase 2Start 2020-07
  18. Hepatobiliary Tumors Tissue Samples AcquisitionStatus unknownNCT04445532Lead sponsorStart 2020-10
  19. Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCCStatus unknownNCT04443309Lead sponsorPhase 1/Phase 2Start 2020-09
  20. FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination TherapyStatus unknownNCT05662488Lead sponsorStart 2020-09
  21. 18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular CarcinomaStatus unknownNCT02238769Lead sponsorStart 2014-07
  22. Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.Status unknownNCT02036216Lead sponsorStart 2014-01
  23. A Clinical Study to Evaluate the Clinical Outcomes of Hepatectomy With Nutritional Risk After Preoperative Nutritional SupportStatus unknownNCT01292330Lead sponsorN/AStart 2010-01
  24. Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT ScanStatus unknownNCT01350726Lead sponsorStart 2008-01
  25. Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCCRecruitingNCT07639138Lead (inferred)Phase 2Start 2026-08
  26. Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingNCT07832006Lead (inferred)Phase 2Start 2025-04
  27. Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular CarcinomaNot yet recruitingNCT07866612Study siteN/AStart 2026-12
  28. MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)RecruitingNCT07479485Study sitePhase 1/Phase 2Start 2026-04
  29. NWRD06 DNA Plasmid for HCC After Curative Resection.RecruitingNCT07324304Study sitePhase 2Start 2025-12
  30. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09
  31. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Study sitePhase 2Start 2025-05
  32. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  33. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  34. To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid TumorsRecruitingNCT07594964Study sitePhase 1Start 2025-08
  35. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  36. Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular CarcinomaSuspendedNCT06405061Study sitePhase 2Start 2024-05
  37. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  38. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  39. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  40. Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular CarcinomaCompletedNCT04401800Study sitePhase 2Start 2020-09
  41. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  42. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingNCT04008797Study sitePhase 1/Phase 2Start 2019-07
  43. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  44. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  45. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Study sitePhase 3Start 2018-03
  46. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  47. HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in ChinaStatus unknownNCT02743065Study siteStart 2016-09
  48. A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical ResectionTerminatedNCT01402908Study sitePhase 3Start 2011-08

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 54 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.5%.

Papers led
54
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 111120212022: 131320222023: 151520232024: 7720242025: 772025

15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  2. Recruiting
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06901531

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

  3. Recruiting
    A Study of LY4257496 in Participants With Cancer (OMNIRAY)
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07114601

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  4. Recruiting
    To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07594964

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  5. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  6. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChemotherapy & combined treatmentPeritoneal spread & advanced diseaseImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncologyPathology / laboratory medicine
Papers it led54
  1. IRAK1 promotes gastric cancer progression by activating the PI3K/AKT/mTOR pathway and inducing the M2 polarization of tumor-associated macrophages.2026Chinese medical journalFree full text
  2. TUBB3 (βIII-tubulin) drives gastric cancer progression and poor prognosis by regulating cell cycle and invadopodia formation.2025Cancer biomarkers : section A of Disease markersFree full text
  3. Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach.2025Cancer medicineFree full text
  4. Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial.2025European journal of cancer (Oxford, England : 1990)
  5. Sarcopenic obesity exacerbates gastric cancer prognosis via increased intermuscular and visceral fat accumulation.2025European journal of medical researchFree full text
  6. Innate Immunity in Helicobacter pylori Infection and Gastric Oncogenesis.2025HelicobacterFree full text
  7. CALCR interaction with ANTXR1 drives gastric tumor growth and metastasis via AKT signaling pathway.2025Scientific reportsFree full text
  8. POSTN+ Cancer-Associated Fibroblasts Promote Gastric Cancer Invasion by Activating AKT Signaling.2025Stem cells and development
  9. Treatment strategies for patients with HER2-positive gastric cancer.2024Cancer biology & medicineFree full text
  10. Burden of six major types of digestive system cancers globally and in China.2024Chinese medical journalFree full text
  11. Personalized treatment of well-differentiated gastric neuroendocrine tumors based on clinicopathological classification and grading: A multicenter retrospective study.2024Chinese medical journalFree full text
  12. Preoperative H. pylori Eradication Therapy Facilitates Precise Delineation in Early Gastric Cancer with Current H. pylori Infection.2024Digestive diseases (Basel, Switzerland)RCTFree full text
  13. Profound postinduction hypotension precipitated by immune checkpoint inhibitors: a case report.2024Journal of medical case reportsFree full text
  14. Quercetin promotes ATG5-mediating autophagy-dependent ferroptosis in gastric cancer.2024Journal of molecular histology
  15. A puzzling case report of well-differentiated neuroendocrine tumor mixed with gastric adenocarcinoma of the fundic gland type associated with autoimmune gastritis.2024Science progressFree full text
  16. Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study.2023Acta obstetricia et gynecologica ScandinavicaFree full text
  17. Comprehensive analysis of cuproptosis-related immune biomarker signature to enhance prognostic accuracy in gastric cancer.2023AgingFree full text
  18. Physical activity and cancer risk: a dose-response analysis for the Global Burden of Disease Study 2019.2023Cancer communications (London, England)Free full text
  19. Comparison of the predictive value of pathological response at primary tumor and lymph node status after neoadjuvant chemotherapy in locally advanced gastric cancer.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  20. Tumour-associated macrophages in gastric cancer: From function and mechanism to application.2023Clinical and translational medicineFree full text
  21. Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway.2023Drug development research
  22. Perioperative chemotherapy versus adjuvant chemotherapy treatment for resectable locally advanced gastric cancer: a retrospective cohort study.2023European journal of medical researchFree full text
  23. [68Ga]Ga-FAPI-04 PET MRI/CT in the evaluation of gastric carcinomas compared with [18F]-FDG PET MRI/CT: a meta-analysis.2023European journal of medical researchFree full text
  24. Integrated analysis from multicentre studies identities m7G-related lncRNA-derived molecular subtypes and risk stratification systems for gastric cancer.2023Frontiers in immunologyFree full text
  25. The Roles of Innate Lymphoid Cells in the Gastric Mucosal Immunology and Oncogenesis of Gastric Cancer.2023International journal of molecular sciencesFree full text
  26. Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer.2023JAMA oncology
  27. Expression of p53 and Rb reveal subtypes of gastric neuroendocrine carcinoma with distinct prognosis.2023Journal of neuroendocrinology
  28. Perioperative Enteral Immunonutrition Support for the Immune Function and Intestinal Mucosal Barrier in Gastric Cancer Patients Undergoing Gastrectomy: A Prospective Randomized Controlled Study.2023NutrientsRCTFree full text
  29. Association between Plasma FGF21 Levels and Body Composition in Patients with Gastric Cancer.2023Nutrition and cancer
  30. Dermoscopy and high-frequency ultrasound provide diagnostic clues in a gastric adenocarcinoma with cutaneous metastasis as the initial presentation: A case report.2023Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)Free full text
  31. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.2022BioMed research internationalFree full text
  32. Clinicopathological features, endoscopic features, and treatment analysis of gastric neuroendocrine neoplasms.2022Chinese medical journalFree full text
  33. Endoscopic characteristics in predicting prognosis of biopsy-diagnosed gastric low-grade intraepithelial neoplasia.2022Chinese medical journalFree full text
  34. Small molecules as potential biomarkers of early gastric cancer: A mass spectrometry imaging approach.2022Clinica chimica acta; international journal of clinical chemistry
  35. Characterization of the fecal microbiota in gastrointestinal cancer patients and healthy people.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  36. Gastroblastoma Treated by Endoscopic Submucosal Excavation with a Novel PTCH1::GLI2 Fusion: A Rare Case Report and Literature Review.2022Current oncology (Toronto, Ont.)Free full text
  37. Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer.2022Current oncology (Toronto, Ont.)Free full text
  38. Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study.2022European journal of nuclear medicine and molecular imaging
  39. Appendiceal Neuroendocrine Tumor Is a Rare Cause of Ectopic Adrenocorticotropic Hormone Syndrome With Cyclic Hypercortisolism: A Case Report and Literature Review.2022Frontiers in endocrinologyFree full text
  40. Visceral Adipose Tissue Assessment Enhances the Prognostic Value of GLIM Criteria in Patients with Gastric Cancer Undergoing Radical Gastrectomy after Neoadjuvant Treatment.2022NutrientsFree full text
  41. Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer.2022TheranosticsFree full text
  42. High incidence combination of multiple primary malignant tumors of the digestive system.2022World journal of gastroenterologyFree full text
  43. Does postoperative chemotherapy improve overall survival of patients with ypT1-2N0 cancer?2022World journal of surgical oncologyFree full text
  44. CT Radiomics for Distinction of Human Epidermal Growth Factor Receptor 2 Negative Gastric Cancer.2021Academic radiology
  45. Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.2021BMC medicineFree full text
  46. Changes in gastric mucosal microbiota in gastric carcinogenesis: a systematic review protocol.2021BMJ openFree full text
  47. Serum phospholipids are potential biomarkers for the early diagnosis of gastric cancer.2021Clinica chimica acta; international journal of clinical chemistry
  48. Feasibility of standardized procedures of white light gastroscopy for clinical practice: A multicenter study in China.2021Journal of digestive diseases
  49. Gastrointestinal: Massive gastric juvenile polyposis.2021Journal of gastroenterology and hepatology
  50. Marked loss of adipose tissue during neoadjuvant therapy as a predictor for poor prognosis in patients with gastric cancer: A retrospective cohort study.2021Journal of human nutrition and dietetics : the official journal of the British Dietetic Association
  51. Impact of body composition on clinical outcomes in people with gastric cancer undergoing radical gastrectomy after neoadjuvant treatment.2021Nutrition (Burbank, Los Angeles County, Calif.)
  52. Gastric Cancer Cell-Derived Exosomes Can Regulate the Biological Functions of Mesenchymal Stem Cells by Inducing the Expression of Circular RNA circ_0004303.2021Stem cells and development
  53. Gastric Cancer or Plasmacytoma in a Seemingly Well-Controlled Multiple Myeloma Patient?2021Turkish journal of haematology : official journal of Turkish Society of HaematologyFree full text
  54. Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)2
  1. [Application effects of 3D visualization reconstruction technique in pheochromocytoma/ paraganglioma surgery].2023Zhonghua yi xue za zhi
  2. [Clinicopathological characteristics of rectal neuroendocrine neoplasms].2021Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status21
  1. Prediction of Drug Response in Gastric Cancer Based on 3D BioprintingStatus unknownNCT06792149Lead sponsorStart 2023-10
  2. 68Ga-PMD22 PET/CT Examination Targeting CLDN18.2Status unknownNCT05937919Lead sponsorEarly phase 1Start 2023-05
  3. The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.Status unknownNCT05170542Lead sponsorPhase 2Start 2021-12
  4. Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin AnalogsStatus unknownNCT03812939Lead sponsorStart 2019-01
  5. Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant ChemotherapyStatus unknownNCT03322969Lead sponsorPhase 2Start 2017-08
  6. An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric CancerStatus unknownNCT02668380Lead sponsorStart 2015-09
  7. FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric CancerStatus unknownNCT02226380Lead sponsorPhase 2Start 2013-10
  8. Enhanced Magnifying Endoscopy for Diagnosis of Early Gastric CancerCompletedNCT01617876Lead sponsorStart 2010-03
  9. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Study sitePhase 3Start 2025-05
  10. To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid TumorsRecruitingNCT07594964Study sitePhase 1Start 2025-08
  11. A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingNCT07114601Study sitePhase 1Start 2025-08
  12. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  13. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  14. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  15. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  16. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  17. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  18. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  19. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Study sitePhase 3Start 2018-10
  20. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  21. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Beijing for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Unilateral retinocytoma associated with a variant in the RB1 gene.2020Molecular genetics & genomic medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025

48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led4
  1. Chromoanagenesis in Osteosarcoma.2025Biomolecules
  2. Fine-needle aspiration cytology for the diagnosis of ewing's sarcoma in bone: a case report.2025Diagnostic pathology
  3. A Se Nanoparticle/MgFe-LDH Composite Nanosheet as a Multifunctional Platform for Osteosarcoma Eradication, Antibacterial and Bone Reconstruction.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  4. An update on the roles of circular RNAs in osteosarcoma.2021Cell proliferation
Earlier papers (2016–2020)8
  1. Identification of the Novel Target Genes for Osteosarcoma Therapy Based on Comprehensive Bioinformatic Analysis.2020DNA and cell biology
  2. LINC01133: an emerging tumor-associated long non-coding RNA in tumor and osteosarcoma.2020Environmental science and pollution research international
  3. Isolated diaphragmatic metastasis from periosteal osteosarcoma of the humerus: a case report.2020Journal of cardiothoracic surgery
  4. The long non-coding RNA SPRY4-IT1: An emerging player in tumorigenesis and osteosarcoma.2018Cell proliferation
  5. SPOCD1 promotes cell proliferation and inhibits cell apoptosis in human osteosarcoma.2018Molecular medicine reports
  6. TRIM59 is upregulated and promotes cell proliferation and migration in human osteosarcoma.2016Molecular medicine reports
  7. Meteorin-Like Shows Unique Expression Pattern in Bone and Its Overexpression Inhibits Osteoblast Differentiation.2016PloS one
  8. Long non-coding RNAs: emerging players in osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
All its trials on ClinicalTrials.gov, any status1
  1. Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver TransplantationNot yet recruitingNCT06041490Lead sponsorPhase 2Start 2023-09

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 6 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.1%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 442025

23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatology
Papers it led6
  1. Heterotopic Pancreas Mimicking Gastrointestinal Stromal Tumor on 68 Ga-NOTA-RM26 PET/CT.2026Clinical nuclear medicine
  2. Unraveling the site-specific features in small intestinal stromal tumors: a retrospective study.2025BMC gastroenterology
  3. Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach.2025Cancer medicineFree full text
  4. Three-dimensional bioprinting of patient-derived Gastrointestinal stromal tumor: a novel platform for precision oncology and drug response profiling.2025Journal of nanobiotechnology
  5. Head-to-Head Comparison of [68Ga]Ga-NOTA-RM26 and [18F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study.2025Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  6. Transanal endoscopic microsurgery with alternative neoadjuvant imatinib for localized rectal gastrointestinal stromal tumor: a single center experience with long-term surveillance.2021Surgical endoscopy
Earlier papers (2016–2020)10
  1. Ectopic bronchogenic cyst of the gastric cardia considered to be a gastrointestinal stromal tumor before surgery: a case report.2020BMC surgery
  2. Retroperitoneal fibromatosis presenting as a mesenteric mass: A case report.2020Medicine
  3. Short- and Long-Term Outcomes of Endoscope-Assisted Laparoscopic Wedge Resection for Gastric Submucosal Tumors Adjacent to Esophagogastric Junction.2018Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  4. Transanal Endoscopic Microsurgery for Patients with Rare Rectal Tumors.2018Journal of laparoendoscopic & advanced surgical techniques. Part A
  5. [Transanal endoscopic microsurgery for local excision of rectal gastrointestinal stromal tumors].2018Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. A Novel Curative Treatment Strategy for Patients with Lower Grade Rectal Gastrointestinal Stromal Tumor: Chemoreduction Combined with Transanal Endoscopic Microsurgery.2017Journal of laparoendoscopic & advanced surgical techniques. Part A
  7. Initial application of transanal endoscopic microsurgery for high-risk lower rectal gastrointestinal stromal tumor after imatinib mesylate neoadjuvant chemotherapy: A case report.2017Medicine
  8. Comparison of short- and long-term outcomes of laparoscopic vs open resection for gastric gastrointestinal stromal tumors.2017World journal of gastroenterology
  9. Ghrelin and gastrointestinal stromal tumors.2017World journal of gastroenterology
  10. [Rectal gastrointestinal stromal tumor: a clinical and pathologic analysis].2016Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status1
  1. 68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal TumorStatus unknownNCT05001204Lead sponsorEarly phase 1Start 2021-05

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 7 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
7
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 1120242025: 112025

24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
    Phase
    Early phase 1
    Started
    2021-09
    Registry
    NCT05069220

    Age 1 year to 80 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineRadiation oncologyNeurosurgeryPathology / laboratory medicine
Papers it led7
  1. Global time-trend analysis and projections of disease burden for neuroblastic tumors: a worldwide study from 1990 to 2021.2025Italian journal of pediatrics
  2. 18 F-MFBG PET/CT and MRI in Identifying Brain Metastases in a Posttreatment Neuroblastoma Patient.2024Clinical nuclear medicine
  3. [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma.2023European journal of nuclear medicine and molecular imaging
  4. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.2023International journal of biological sciences
  5. Shear wave elastography for differentiating parathyroid neoplasms with malignant diagnosis or uncertain malignant potential from parathyroid adenomas: initial experience.2022Cancer imaging : the official publication of the International Cancer Imaging Society
  6. Oncogene or tumor suppressor gene: An integrated pan-cancer analysis of NBPF1.2022Frontiers in endocrinology
  7. Risk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database.2021Radiation oncology (London, England)
Earlier papers (2016–2020)2
  1. Acrometastasis of Neuroblastoma to the Great Toe Revealed by MIBG Scan.2017Clinical nuclear medicine
  2. Abnormal FDG and MIBG Activity in the Bones in a Patient With Neuroblastoma Without Detectable Primary Tumor.2016Clinical nuclear medicine
All its trials on ClinicalTrials.gov, any status1
  1. 18F-MFBG PET/CT in the Evaluation of Neural Crest TumorRecruitingNCT05069220Lead sponsorEarly phase 1Start 2021-09

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 27 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.6%.

Papers led
27
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 6620212022: 4420222023: 2220232024: 111120242025: 332025

15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Isa-VRD in TIE HRMM
    Phase
    Phase 4
    Started
    2026-01
    Registry
    NCT07334535

    Age 18 years to 80 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  2. Not yet recruiting
    Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
    Phase
    N/A
    Started
    2026-02
    Registry
    NCT07353554

    Age 18 years to 85 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  3. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  4. Recruiting
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07663253

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou

  5. Recruiting
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06083207

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou

  6. Recruiting
    Risk Stratification and MRD-driven Maintenance for MM After ASCT
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06697483

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Harbin

  7. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  8. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskRelapse & resistanceDrug combinations
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineNeurosurgery
Papers it led27
  1. Total tumor apparent diffusion coefficient histogram analysis of whole-body DWI-MRI for prognostic stratification in patients with R-ISS stage II multiple myeloma.2026Magnetic resonance imaging
  2. Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.2025Acta haematologicaFree full text
  3. Clonal Hematopoietic Mutations in Plasma Cell Disorders: Clinical Subgroups and Shared Pathogenesis.2025Genomics, proteomics & bioinformaticsFree full text
  4. Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab.2025Journal of translational medicineFree full text
  5. Total Tumor ADC Histogram Analysis: A New Tool for Predicting High-Risk Cytogenetic Abnormalities in Multiple Myeloma Patients.2024Academic radiology
  6. Myc rearrangement redefines the stratification of high-risk multiple myeloma.2024Cancer medicineFree full text
  7. M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma.2024Clinica chimica acta; international journal of clinical chemistry
  8. Chemokine Receptor 4-Targeted PET/CT With 68 Ga-Pentixather Detects More Lesions Than 68 Ga-Pentixafor PET/CT in Multiple Myeloma.2024Clinical nuclear medicine
  9. MYC translocation is a valuable marker for the development and relapse of extramedullary disease in multiple myeloma.2024European journal of haematology
  10. Identifying immune checkpoints on dysregulated T-cells as prognostic biomarkers for multiple myeloma patients with COVID-19.2024Frontiers in immunologyFree full text
  11. Impaired acute-phase humoral immunity is the major factor predicting unfavorable outcomes in multiple myeloma patients with SARS-CoV-2 Omicron variants outbreak infection.2024International journal of cancer
  12. BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.2024Journal for immunotherapy of cancerFree full text
  13. Treatment Response Assessment in Multiple Myeloma: Histogram Analysis of Total Tumor Apparent Diffusion Coefficient based on Whole-body Diffusion-weighted MR Imaging.2024Journal of magnetic resonance imaging : JMRI
  14. Daratumumab-based regimen for cold agglutinin disease refractory to therapy directing B-cell clone.2024Leukemia & lymphoma
  15. Chemokine Receptor 4-Targeted PET/CT with [68Ga]pentixather in Newly Diagnosed Multiple Myeloma: a Comparative Study with [68Ga]pentixafor PET/CT.2024Molecular imaging and biology
  16. A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD.2023Blood
  17. Front-line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real-world setting: A multicenter retrospective study in China.2023Cancer medicineFree full text
  18. Histogram Analysis Based on Apparent Diffusion Coefficient Maps of Bone Marrow in Multiple Myeloma: An Independent Predictor for High-risk Patients Classified by the Revised International Staging System.2022Academic radiology
  19. 68Ga-Pentixafor PET/CT Improves the Detection of Recurrent Myeloma in the Temporal Bone Masked by the Physiological 18F-FDG Uptake of the Brain and Extraocular Muscles.2022Clinical nuclear medicine
  20. Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis.2022Leukemia
  21. A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD.2022Leukemia & lymphoma
  22. The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma.2021Annals of hematology
  23. Increased Uptake of 68Ga-Pentixafor in Thymic Rebound After Chemotherapy in a Patient With Multiple Myeloma.2021Clinical nuclear medicine
  24. Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma.2021European radiology
  25. Multiple myeloma complicated by skull plasmacytoma discovered after head injury.2021Journal of integrative neuroscience
  26. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.2021Scientific reportsFree full text
  27. Gastric Cancer or Plasmacytoma in a Seemingly Well-Controlled Multiple Myeloma Patient?2021Turkish journal of haematology : official journal of Turkish Society of HaematologyFree full text
Chinese-language papers (not in the count)9
  1. [Value of gene mutation in the prognosis and treatment of multiple myeloma].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [The 505th case: refractory ascites and monoclonal immunoglobulin].2024Zhonghua nei ke za zhi
  3. [Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib, cyclophosphamide, and dexamethasone].2023Zhonghua nei ke za zhi
  4. [Efficacy and prognostic analysis of orthopedic surgery in patients with newly diagnosed multiple myeloma].2023Zhonghua nei ke za zhi
  5. [The influencing factors of renal response in newly diagnosed multiple myeloma patients with renal impairment].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  6. [A case of multiple myeloma accompanied with breast cancer and lung cancer].2022Zhonghua nei ke za zhi
  7. [Chronic myelomonocytic leukemia accompanied with multiple myeloma: a case report].2022Zhonghua nei ke za zhi
  8. [Analysis of the efficacy and survival of ixazomib-containing regimens in patients with refractory and relapsed multiple myeloma].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  9. [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status35
  1. Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple MyelomaNot yet recruitingNCT07353554Lead sponsorN/AStart 2026-02
  2. Isa-VRD in TIE HRMMNot yet recruitingNCT07334535Lead sponsorPhase 4Start 2026-01
  3. Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received LenalidomideStatus unknownNCT04989140Lead sponsorPhase 4Start 2021-07
  4. 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple MyelomaStatus unknownNCT05364177Lead sponsorEarly phase 1Start 2021-08
  5. Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple MyelomaStatus unknownNCT03711864Lead sponsorPhase 1Start 2019-02
  6. A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaStatus unknownNCT04295018Lead sponsorPhase 1Start 2019-10
  7. Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and LymphomaStatus unknownNCT03436342Lead sponsorEarly phase 1Start 2019-06
  8. Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM PatientsCompletedNCT04217967Lead sponsorPhase 4Start 2019-09
  9. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  10. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Study siteStart 2026-06
  11. Risk Stratification and MRD-driven Maintenance for MM After ASCTRecruitingNCT06697483Study siteN/AStart 2024-12
  12. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT06083207Study sitePhase 1/Phase 2Start 2024-07
  13. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  14. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  15. A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT07266441Study sitePhase 2Start 2026-02
  16. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  17. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  18. A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT06223646Study sitePhase 1/Phase 2Start 2024-01
  19. A Clinical Trial of TQB2934 for Injection in Multiple Myeloma SubjectsStatus unknownNCT05646758Study sitePhase 1Start 2023-03
  20. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  21. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  22. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Study sitePhase 2Start 2021-12
  23. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05
  24. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Study sitePhase 3Start 2019-01
  25. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  26. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  27. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  28. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03
  29. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  30. An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma ParticipantsTerminatedNCT02761187Study siteStart 2016-07
  31. Ixazomib Rollover StudyCompletedNCT02924272Study sitePhase 2Start 2016-12
  32. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Study sitePhase 3Start 2015-04
  33. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07
  34. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Study sitePhase 2Start 2012-09
  35. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Study sitePhase 2Start 2010-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 1 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

10 hospitals in Beijing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Registry
    NCT06481735

    Age 16 years to 70 years (registered criteria)

    Led by Chinese PLA General Hospital; 3 listed hospitals as study sitesBeijing, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibody & targeted drugs

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 16 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 3.9%.

Papers led
16
2021–2025
Trials led
19
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 6620232024: 2220242025: 442025

6 hospitals in Beijing for aplastic anaemia63 hospitals in China for aplastic anaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06802055

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesThrombopoietin drugsImmunosuppressive treatmentInfection & supportive care
Papers it led16
  1. Exploration of B- and T-Cell Receptor Repertoires Reveals Distinct Mechanisms in Pure Red Cell Aplasia, Autoimmune Hemolytic Anemia, and Aplastic Anemia.2026Acta haematologicaFree full text
  2. Long-Term Follow-Up of Eltrombopag Treatment for Patients with Cyclosporin A Refractory/Relapsed Transfusion-Dependent Non-Severe Aplastic Anemia: A Report from a Single Center in China.2025Acta haematologicaFree full text
  3. Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study.2025Annals of medicineFree full text
  4. Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study.2025Blood cancer journalRCTFree full text
  5. Adding recombinant human thrombopoietin to cyclosporine A and hetrombopag enhances the early hematologic response in transfusion-dependent non-severe aplastic anemia: a retrospective study.2025Hematology (Amsterdam, Netherlands)
  6. Cyclosporine plus avatrombopag versus cyclosporine monotherapy for first-line treatment of elderly patients with transfusion-dependent non-severe aplastic anemia: a single center retrospective study.2024Annals of medicineFree full text
  7. High- vs regular-dose recombinant human thrombopoietin plus cyclosporine A in patients with newly diagnosed non-severe aplastic anemia: a retrospective cohort study.2024Hematology (Amsterdam, Netherlands)
  8. Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial.2023Annals of medicineFree full text
  9. Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial.2023Blood cancer journalRCTFree full text
  10. Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers.2023Chinese medical journalFree full text
  11. Plasma lipidome acts as diagnostic marker and predictor for cyclosporin response in patients with aplastic anemia.2023Clinical and experimental medicine
  12. Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study.2023European journal of haematology
  13. Avatrombopag is effective in patients with chemoradiotherapy-induced aplastic anemia: a single-center, retrospective study.2023Experimental hematology
  14. Severe aplastic anemia in a patient with erythropoietic protoporphyria successfully treated by avatrombopag.2022Annals of hematology
  15. Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia.2022Journal of clinical pharmacy and therapeutics
  16. Effective treatment of aplastic anemia secondary to chemoradiotherapy using cyclosporine A.2021Chinese medical journalFree full text
Chinese-language papers (not in the count)4
  1. [Efficacy and safety of lusutrombopag monotherapy for cyclosporine A-refractory, transfusion-dependent non-severe aplastic anemia].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [Efficacy and safety of roxadustat in the treatment of refractory non-severe aplastic anemia].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  3. [Clinical characteristics and prediction model of early death in severe/very severe aplastic anemia with immunosuppressive therapy].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  4. [Efficacy of stanozolol and danazol in the treatment of non-severe aplastic anemia and their effects on CD4(+)CD25(+)Foxp3(+) regulatory T cells].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status19
  1. Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin ARecruitingNCT06802055Lead sponsorPhase 2Start 2025-01
  2. Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAAWithdrawnNCT06424639Lead sponsorPhase 4Start 2024-05
  3. A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAAStatus unknownNCT06535685Lead sponsorPhase 4Start 2024-08
  4. Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm StudyStatus unknownNCT06516484Lead sponsorPhase 4Start 2024-07
  5. Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAAStatus unknownNCT06525948Lead sponsorPhase 4Start 2024-07
  6. A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With LusutrombopagStatus unknownNCT06426043Lead sponsorPhase 4Start 2024-06
  7. CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the ElderlyCompletedNCT05996393Lead sponsorPhase 4Start 2023-09
  8. Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAAStatus unknownNCT06009497Lead sponsorPhase 4Start 2023-08
  9. Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction SystemStatus unknownNCT06009965Lead sponsorPhase 4Start 2023-01
  10. A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAAStatus unknownNCT06004791Lead sponsorPhase 4Start 2023-08
  11. Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the ElderlyStatus unknownNCT06004752Lead sponsorPhase 2Start 2023-08
  12. Avatrombopag Usage in NSAAStatus unknownNCT04728789Lead sponsorPhase 2/Phase 3Start 2021-02
  13. Efficacy and Safety of Hetrombopag in Non-severe Aplastic AnemiaWithdrawnNCT05018936Lead sponsorPhase 2/Phase 3Start 2021-10
  14. Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia PatientsCompletedNCT04403321Lead sponsorPhase 2Start 2020-07
  15. Tacrolimus Treatment for Refractory Autoimmune CytopeniaStatus unknownNCT03918265Lead sponsorPhase 4Start 2019-05
  16. Tacrolimus Treatment for Refractory PRCAStatus unknownNCT03540472Lead sponsorPhase 4Start 2018-06
  17. Efficacy and Safety in Transfusion Independent Non-severe Aplastic AnemiaCompletedNCT05399732Lead (inferred)Phase 2Start 2022-12
  18. Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCACompletedNCT04470804Lead (inferred)Phase 4Start 2020-07
  19. Sirolimus Treatment for Refractory PRCACompletedNCT03364764Lead (inferred)Phase 4Start 2018-02

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 7 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 1.8%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 2220242025: 222025

11 hospitals in Beijing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07208058

    Age 16 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesLymphoma & cancer-related HLHGenetics & inherited formsTreatment regimens
Departments in papersRheumatology & immunologyPediatrics
Papers it led7
  1. CHOP is insufficient for newly-diagnosed subcutaneous panniculitis-like T-cell lymphoma patients: a retrospective study of 32 patients in China.2025BMC cancerFree full text
  2. Germline defects of familial haemophagocytic lymphohistiocytosis-Related genes may represent a predisposing factor for mature T- and natural killer-cell lymphoma.2025British journal of haematologyFree full text
  3. Disseminated tuberculosis complicated by intramuscular abscesses, meningoencephalitis, and hemophagocytic lymphohistiocytosis: a case report.2024BMC infectious diseasesFree full text
  4. Germline defects of familial hemophagocytic lymphohistiocytosis-related genes presenting as adult-onset peripheral T-cell lymphoma.2024Frontiers in immunologyFree full text
  5. Case Report: Missing zinc finger domains: hemophagocytic lymphohistiocytosis in a GATA2 deficiency patient triggered by non-tuberculous mycobacteriosis.2023Frontiers in immunologyFree full text
  6. Reversal of SLE and hemophagocytic lymphohistiocytosis caused by lysinuric protein intolerance through allogeneic hematopoietic stem cell transplantation.2023The Journal of allergy and clinical immunology
  7. Management of hemophagocytic lymphohistiocytosis in pregnancy: Case series study and literature review.2022The journal of obstetrics and gynaecology researchFree full text
Chinese-language papers (not in the count)3
  1. [Recommendations for the diagnosis and treatment of rheumatic diseases-related hemophagocytic syndrome in China].2023Zhonghua nei ke za zhi
  2. [Assessment of MS-Score and HScore in timeliness of diagnosis of macrophage activation syndrome associated with adult-onset Still's disease].2022Zhonghua yi xue za zhi
  3. [Progress of targeted therapy in macrophage activation syndrome secondary to autoimmune diseases].2021Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status2
  1. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])RecruitingNCT07208058Study sitePhase 3Start 2025-11
  2. A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))CompletedNCT07034209Study sitePhase 2Start 2023-04
More papers found outside PubMed (not counted)4
  1. IFN-γ-induced CD4+ CADM1+ T cells emerged as malignancy-progressive biomarkers in EBV NK/T lymphoproliferative disorders and potential drivers of malignant expansion in AITL2025Bloodconference-abstract
  2. CHOP Is Insufficient for Newly-Diagnosed Subcutaneous Panniculitis-like T-Cell Lymphoma Patients: A Retrospective Study of 32 Patients in China2024Bloodconference-abstract
  3. Chemo-Free Salvage Treatment Is Better Than Traditional Chemotherapy in Relapsed/Refractory Subcutaneous Panniculitis-like T-Cell Lymphoma2024Bloodconference-abstract
  4. Pattern and Prognosis of Distant Metastases in Patients with Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma2022International Journal of Radiation Oncology*Biology*Physicsarticle

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

10 hospitals in Beijing for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 17 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 6.2%.

Papers led
17
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 4420212022: 3320222023: 4420232024: 5520242025: 112025

15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07416604

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Tianjin

  2. Recruiting
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06833983

    Age 18 years to 65 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou

  3. Recruiting
    Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
    Phase
    Phase 2/Phase 3
    Started
    2024-01
    Registry
    NCT06111638

    Age 18 years to Not stated; men only (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi’an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatrics
Papers it led17
  1. Analysis of the current status and characteristics of osteoporosis in adult hemophilia patients based on high-resolution peripheral quantitative computed tomography: a case control study.2025BMC musculoskeletal disorders
  2. Absence of femur induced by haemophilic pseudotumour.2024British journal of haematology
  3. Renal inflammatory myofibroblastic tumor coexisting with hemophilia A carrier: a case report and literature review.2024CEN case reports
  4. Chain-mediating effects of kinesiophobia and self-efficacy on pain catastrophizing and physical activity in haemophilia patients.2024Haemophilia : the official journal of the World Federation of Hemophilia
  5. Incidence and treatment-related risk factors of inhibitor development after intensive FVIII replacement for major orthopaedic surgery in previous treated haemophilia A.2024Journal of orthopaedic surgery and research
  6. Present status of scheduled vaccinations and vaccination-related bleeding in Chinese children with haemophilia.2024Journal of paediatrics and child health
  7. Pathogenesis and treatment of osteoporosis in patients with hemophilia.2023Archives of osteoporosis
  8. Long-term clinical outcomes following total knee arthroplasty in patients with hemophilic arthropathy: a single-surgeon cohort after a 10- to 17-year follow-up.2023Chinese medical journal
  9. Associations between bullous pemphigoid and hematological diseases: Literature review on mechanistic connections and possible treatments.2023Frontiers in immunology
  10. A Novel Surgical Classification for Extremity and Pelvic Hemophilic Pseudotumors: The PUMCH Classification.2023The Journal of bone and joint surgery. American volume
  11. Replacement Therapy for Hemophilia Patients Undergoing Cardiac Surgery: Report of Three Cases.2022Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  12. Risk Factors for Amputation in the Surgical Treatment of Hemophilic Osteoarthropathy: A 20-Year Single-Center Report.2022Pain research & management
  13. Mapping the Haem-A-QoL to the EQ-5D-5L in patients with hemophilia.2022Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
  14. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.2021Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  15. Long-term joint outcomes of regular low-dose prophylaxis in Chinese children with severe haemophilia A.2021Haemophilia : the official journal of the World Federation of Hemophilia
  16. Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia.2021The European journal of health economics : HEPAC : health economics in prevention and care
  17. Conservative therapy for spinal epidural hematoma in a child with hemophilia A with high-titer VIII inhibitors.2021The Journal of international medical research
Chinese-language papers (not in the count)2
  1. [Long-term health-related quality of life and related factors in children with severe hemophilia A who received regular low-dose prophylaxiss].2024Zhonghua yi xue za zhi
  2. [How I diagnose and treat acquired hemophilia A].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Earlier papers (2016–2020)30
  1. Early wound complications after orthopaedic surgery for haemophilia: What can we do more.2020Haemophilia : the official journal of the World Federation of Hemophilia
  2. Complications of total knee arthroplasty in patients with haemophilia compared with osteoarthritis and rheumatoid arthritis: A 20-year single-surgeon cohort.2020Haemophilia : the official journal of the World Federation of Hemophilia
  3. Severe haemophilia A children on low-dose tertiary prophylaxis showed less joint deterioration and better maintenance of functional independence than children on on-demand treatment: A 6-year follow-up study.2020Haemophilia : the official journal of the World Federation of Hemophilia
  4. Bleeding assessment in haemophilia carriers-High rates of bleeding after surgical abortion and intrauterine device placement: A multicentre study in China.2020Haemophilia : the official journal of the World Federation of Hemophilia
  5. Hemophilic Pseudotumor.2020The New England journal of medicine
  6. [Orthopedic treatment of musculoskeletal disorders in hemophilic patients].2020Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  7. Survey of non-physiotherapy department medical staff in China and their understanding of physiotherapy in comprehensive management of haemophilia.2019Haemophilia : the official journal of the World Federation of Hemophilia
  8. Surgical Management of Haemophilic Pseudotumors: Experience in a Developing Country.2019Journal of investigative surgery : the official journal of the Academy of Surgical Research
  9. Incidence of Symptomatic Venous Thromboembolism in Patients with Hemophilia Undergoing Hip and Knee Joint Replacement without Chemoprophylaxis: A Retrospective Study.2019Orthopaedic surgery
  10. Successful treatment of giant abdominal haemophilic pseudotumours causing hydronephrosis.2019Postgraduate medical journal
  11. Management of knee flexion contracture in haemophilia with the Ilizarov technique.2019The Knee
  12. [Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A].2019Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  13. Pelvi-Femoral Complete Bone Bridge in a Patient with Hemophilia.2018Chinese medical journal
  14. Application of optimized nursing process to perioperative patients with haemophilic pseudotumours.2018Haemophilia : the official journal of the World Federation of Hemophilia
  15. Influence of medical insurance schemes and charity assistance projects on regular prophylaxis treatment of the boys with severe haemophilia A in China.2018Haemophilia : the official journal of the World Federation of Hemophilia
  16. Hemophilic arthropathy in a patient with multi-joint replacement: A case report and literature review.2018Medicine
  17. Simultaneous bilateral total knee arthroplasty in patients with end-stage hemophilic arthropathy: a mean follow-up of 6 years.2018Scientific reports
  18. Efficacy of a modified coagulation factor substitution for total hip arthroplasty in patients with end-stage haemophilic arthropathy.2017Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  19. An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A.2017Clinical therapeutics
  20. Surgical treatment of a giant iliopsoas haemophilic pseudotumour with adjacent structure compressions: A case report.2017Haemophilia : the official journal of the World Federation of Hemophilia
  21. Serological biomarkers detect active joint destruction and inflammation in patients with haemophilic arthropathy.2017Haemophilia : the official journal of the World Federation of Hemophilia
  22. Low-dose factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption.2017Haemophilia : the official journal of the World Federation of Hemophilia
  23. Open repair of intraoperative popliteal artery injury during total knee arthroplasty in a patient with severe hemophilia A: A case report and literature review.2017Medicine
  24. Total Hip Arthroplasty in Hemophilia Patients: A Mid-term to Long-term Follow-up.2017Orthopaedic surgery
  25. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.2017Pediatric hematology and oncology
  26. Surgical Treatment for Hemophilic Pseudotumor: Twenty-three Cases with an Average Follow-up of 5 Years.2017The Journal of bone and joint surgery. American volume
  27. Coexistence of acquired hemophilia A and epidermolysis bullosa acquisita: Two case reports and published work review.2017The Journal of dermatology
  28. Moderate-intensity exercise improves the thromboelastography coagulation index in children with severe hemophilia A.2016Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  29. Analyses of joint health and influencing factors in different age groups of Chinese children with haemophilia.2016Haemophilia : the official journal of the World Federation of Hemophilia
  30. Perioperative Period of a Hemophilia-related Osteoarthropathy Therapeutic Regimen and Analysis of Complications.2016Orthopaedic surgery
All its trials on ClinicalTrials.gov, any status9
  1. A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia ARecruitingNCT07416604Study sitePhase 3Start 2026-04
  2. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia ARecruitingNCT06833983Study sitePhase 3Start 2025-03
  3. Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy DrugsRecruitingNCT06111638Study sitePhase 2/Phase 3Start 2024-01
  4. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedNCT05707351Study sitePhase 3Start 2023-03
  5. A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia ACompletedNCT04565236Study sitePhase 4Start 2020-09
  6. Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A ParticipantsCompletedNCT03315455Study sitePhase 3Start 2018-04
  7. Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia ACompletedNCT02461992Study sitePhase 1Start 2015-07
  8. A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care TreatmentCompletedNCT02476942Study siteStart 2015-05
  9. China ADVATE PTP StudyCompletedNCT02170402Study sitePhase 4Start 2014-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

6 hospitals in Beijing for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Clinical presentation and management of acquired thrombotic thrombocytopenic purpura: A case series of 55 patients.2021Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Earlier papers (2016–2020)7
  1. Cholangiocarcinoma presenting with acquired thrombotic thrombocytopenic purpura confirmed by positive autoantibodies of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13.2020Chinese medical journal
  2. Successful treatment of refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with combination of plasma exchange and low-dose rituximab.2020Lupus
  3. Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study.2020Orphanet journal of rare diseases
  4. First case report of bacteremia caused by Solobacterium moorei in China, and literature review.2019BMC infectious diseases
  5. Clinical features and prognosis of patients with thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a review of 25 cases.2019Italian journal of pediatrics
  6. Sjögren's syndrome initially presented as thrombotic thrombocytopenic purpura in a male patient: a case report and literature review.2018Clinical rheumatology
  7. [The 466th case:myasthenia,fever,blurred vision and pancytopenia].2018Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status2
  1. Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTPStatus unknownNCT05135442Lead sponsorPhase 4Start 2021-12
  2. A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraActive, not recruitingNCT04683003Study sitePhase 3Start 2021-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 8 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.7%.

Papers led
8
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 1120242025: 222025

12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosisImagingOptic nerve & vision
Departments in papersNeurologyOphthalmology / neuro-ophthalmology
Papers it led8
  1. Choroidal structure differs between multiple sclerosis and neuromyelitis optica spectrum disorder: An enhanced depth imaging optical coherence tomography study.2026Multiple sclerosis and related disorders
  2. Neuromyelitis optica spectrum disorders with recurrent syncope due to area postrema syndrome: a case report and literature review.2025BMC neurologyFree full text
  3. Advances in maintenance therapies for neuromyelitis optica spectrum disorders: A new era of targeted drugs.2025Multiple sclerosis and related disorders
  4. Retinal structural and microvascular deterioration independent of optic neuritis in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders: An optical coherence tomography angiography study.2024Multiple sclerosis and related disorders
  5. Aquaporin-4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with Immunosuppressants.2023Annals of neurology
  6. Factors correlated with neuropathic pain in patients with neuromyelitis optica spectrum disorder.2022Multiple sclerosis and related disorders
  7. Review of Neuromyelitis Optica Spectrum Disorder with Pain-Depression Comorbidity.2021Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  8. Patients with neuromyelitis optica spectrum disorder (NMOSD) are associated with adverse outcome after total hip arthroplasty: a matched case-control study.2021Orphanet journal of rare diseasesFree full text
Chinese-language papers (not in the count)1
  1. [Clinical characteristics in 40 patients with longitudinally extensive transverse myelitis and connective tissue disease].2021Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderStatus unknownNCT05284175Lead sponsorN/AStart 2022-04
More papers found outside PubMed (not counted)1
  1. Aquaporin-4 antibody dynamics and relapse risk in seropositive neuromyelitis optica spectrum disorder treated with immunosuppressants2023Journal of the Neurological Sciencesarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 47 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 19.1%.

Papers led
47
2021–2025
Trials led
21
any status, ClinicalTrials.gov
Open trials led
7
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 101020212022: 8820222023: 9920232024: 9920242025: 882025

11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
    Phase
    Phase 2/Phase 3
    Started
    2025-07
    Registry
    NCT07068165

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  2. Recruiting
    A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
    Phase
    N/A
    Started
    2025-05
    Registry
    NCT07104058

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  3. Recruiting
    Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
    Phase
    N/A
    Started
    2022-07
    Registry
    NCT05789030

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  4. Recruiting
    National Registry of IgG4-RD in China
    Phase
    Not given
    Started
    2016-12
    Registry
    NCT03023371

    Age not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  5. Recruiting
    A Prospective Cohort Study of IgG4RD in China
    Phase
    Not given
    Started
    2012-01
    Registry
    NCT01670695

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  6. Not yet recruiting
    Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
    Phase
    Early phase 1
    Started
    2026-10
    Registry
    NCT07806045

    Age 18 years to 80 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  7. Not yet recruiting
    Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07878585

    Age 45 years to 79 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  8. Recruiting
    Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07061938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Shanghai, Wuhan

  9. Not yet recruiting
    Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07222553

    Age 2 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changsha

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesTreatment & relapseDiagnosis & look-alikesHead, eye socket & salivary glands
Departments in papersRheumatology & immunologyPathology / laboratory medicineRadiology / nuclear medicineGastroenterology / hepatology
Papers it led47
  1. Allergen-Specific IgE and IgG4 Signatures in IgG4-Related Disease Revealed by a Large-Scale PhIP-Seq Study.2026Allergy
  2. Genome-wide association studies reveal new insights into the genetic basis of IgG4-related disease in the Chinese Han population.2026Annals of the rheumatic diseases
  3. Evaluating and predicting disease damage accumulation of IgG4-RD over ten years: utility of the IgG4-related Disease Damage Index.2026Clinical and experimental rheumatology
  4. Elevated eosinophil-to-lymphocyte ratio (ELR) as a predictor of relapse for IgG4-related disease: a retrospective study across a decade.2025Clinical and experimental medicineFree full text
  5. IgG4-related disease with comorbid autoimmune diseases: a retrospective study from a large cohort.2025Clinical rheumatology
  6. Clinical and prognostic profiles in immune-mediated hypertrophic meningitis: a retrospective analysis of 92 cases.2025Clinical rheumatology
  7. Exploring the clinical characteristics and long-term outcome of serologically active clinically quiescent IgG4-related disease: knowledge from a prospective cohort.2025Clinical rheumatology
  8. Polarization of Vδ2 T cells to a Th2-like phenotype promotes plasmablast differentiation and possesses pro-fibrotic properties in IgG4-related disease.2025Frontiers in immunologyFree full text
  9. Efficacy and safety of anti-CD19 CAR-T in a mouse model of IgG4-related disease.2025International immunopharmacology
  10. Differences in Fibroinflammatory Activity Shown on 68Ga-FAPI-04 and 18F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease.2025Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  11. Clinical and Radiologic Differences in Lung Involvement Between IgG4-Related Disease and Plasma Cell-Type Idiopathic Multicentric Castleman Disease.2025Lung
  12. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.2024Annals of the rheumatic diseasesRCT
  13. Comparison of clinical features and outcomes of proliferative, fibrotic, and mixed subtypes of IgG4-related disease: A retrospective cohort study.2024Chinese medical journalFree full text
  14. Effectiveness of tofacitinib monotherapy for patients with IgG4-RD or idiopathic retroperitoneal fibrosis.2024Clinical and experimental rheumatology
  15. Expansion and surface makers of age-associated B cells in IgG4-related disease.2024Clinical and experimental rheumatology
  16. Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis.2024European journal of internal medicine
  17. Revealing the distinct clinical patterns and relapse risk factors in seronegative IgG4-RD patients: A retrospective cohort study over a decade.2024Journal of internal medicine
  18. Coronary periarteritis and pericarditis are rare but distinct manifestations of heart involvement in IgG4-related disease: a retrospective cohort study.2024Orphanet journal of rare diseasesFree full text
  19. The development and initial validation of IgG4-related disease damage index: a consensus report from Chinese IgG4-RD Consortium.2024RMD openFree full text
  20. Sex bias in IgG4-related disease: from clinical phenotype to mechanisms.2024The Lancet. Rheumatology
  21. Differential CpG DNA methylation of peripheral B cells, CD4+ T cells, and salivary gland tissues in IgG4-related disease.2023Arthritis research & therapyFree full text
  22. Coronary artery ectasia associated with IgG4-related disease: a case report and literature review.2023BMC cardiovascular disordersFree full text
  23. Memory CD4+T cell profile is associated with unfavorable prognosis in IgG4-related disease: Risk stratification by machine-learning.2023Clinical immunology (Orlando, Fla.)
  24. Prominent 68 Ga-FAPI Uptake in Renal Parenchyma Caused by Immunoglobulin G4-Related Nephropathy.2023Clinical nuclear medicine
  25. Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study.2023Clinical rheumatology
  26. Confusions and challenges in the diagnosis of IgG4-related disease.2023International journal of rheumatic diseases
  27. A unified serum IgG4 cut-off level for the diagnosis of IgG4-related disease using a wide array of kits.2023Modern rheumatology
  28. Potential impact of autoimmune diseases family history in IgG4-related disease: a retrospective cohort study.2023RMD openFree full text
  29. The external validation of the 2019 ACR/EULAR classification criteria for IgG4-related disease in a large cohort from China.2023Seminars in arthritis and rheumatism
  30. Distinct metabolic biomarkers to distinguish IgG4-related disease from Sjogren's syndrome and pancreatic cancer and predict disease prognosis.2022BMC medicineFree full text
  31. Severe asthma as the initial clinical manifestation of IgG4-related disease: a retrospective clinical study.2022BMC pulmonary medicineFree full text
  32. Expanded CD4+CXCR5-PD-1+ peripheral T helper like cells and clinical significance in IgG4-related disease.2022Clinical immunology (Orlando, Fla.)
  33. Single-Cell Sequencing of Immune Cell Heterogeneity in IgG4-Related Disease.2022Frontiers in immunologyFree full text
  34. Prediction of new organ onset in recurrent immunoglobulin G4-related disease during 10 years of follow-up.2022Journal of internal medicine
  35. TSLP promoting B cell proliferation and polarizing follicular helper T cell as a therapeutic target in IgG4-related disease.2022Journal of translational medicineFree full text
  36. Human epididymis protein 4 (HE4) is a novel biomarker for fibrosis in IgG4-related disease and can predict poor prognosis.2022RMD openFree full text
  37. Phenotype, function and clinical significance of innate lymphoid cells in immunoglobulin G4-related disease.2022Rheumatology (Oxford, England)
  38. Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study.2021Arthritis research & therapyFree full text
  39. Ophthalmic involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 573 patients.2021BMC ophthalmologyFree full text
  40. The association of different serum IgG4 levels with distinct clinical characteristics and treatment efficacy in patients with IgG4-related disease.2021Clinical and experimental rheumatology
  41. Assessing serum IgG4 glycosylation profiles of IgG4-related disease using lectin microarray.2021Clinical and experimental rheumatology
  42. Multiple nodules under the pericardium in a patient with IgG4-related disease.2021Clinical rheumatology
  43. Peripheral B-Cell Immunophenotyping Identifies Heterogeneity in IgG4-Related Disease.2021Frontiers in immunologyFree full text
  44. Proteomic analyses of plasma-derived exosomes in immunoglobulin (Ig) G4-related disease and their potential roles in B cell differentiation and tissue damage.2021Journal of autoimmunity
  45. Fibroblast Activation Protein-Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT.2021Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  46. Clinical features and treatment efficacy for IgG4-related thyroiditis.2021Orphanet journal of rare diseasesFree full text
  47. Differences in clinical characteristics of IgG4-related disease across age groups: a prospective study of 737 patients.2021Rheumatology (Oxford, England)
Chinese-language papers (not in the count)3
  1. [Research progress in IgG4-related disease over the recent decade].2024Zhonghua nei ke za zhi
  2. [Recommendations for the diagnosis and treatment of IgG4-related disease in China].2023Zhonghua nei ke za zhi
  3. [The similar characteristics of IgG4-related disease and allergic diseases].2023Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
All its trials on ClinicalTrials.gov, any status24
  1. Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related DiseaseNot yet recruitingNCT07878585Lead sponsorPhase 2Start 2026-09
  2. A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related DiseaseRecruitingNCT07068165Lead sponsorPhase 2/Phase 3Start 2025-07
  3. Treatment Strategies for IgG4-RD Patients With Superficial Organ InvolvementRecruitingNCT05789030Lead sponsorN/AStart 2022-07
  4. National Registry of IgG4-RD in ChinaRecruitingNCT03023371Lead sponsorStart 2016-12
  5. A Prospective Cohort Study of IgG4RD in ChinaRecruitingNCT01670695Lead sponsorStart 2012-01
  6. Treatment Strategies in IgG4-RD Patients With Re-elevation of Serum IgG4 Level During Maintenance Remission PeriodStatus unknownNCT05974683Lead sponsorN/AStart 2023-08
  7. Treatment Strategies for IgG4-RD Patients With Internal Organ InvolvementStatus unknownNCT05789017Lead sponsorN/AStart 2022-07
  8. Belimumab Treatment for IgG4-related DiseaseStatus unknownNCT04660565Lead sponsorPhase 4Start 2021-01
  9. Circulating Plasmablast in Diagnosis and Relapse Prediction of IgG4-RDStatus unknownNCT04539197Lead sponsorStart 2020-06
  10. Withdraw Drug in Stable IgG4-Related DiseaseStatus unknownNCT04124861Lead sponsorN/AStart 2020-06
  11. Characterizing IgG4-RD With 68Ga-FAPI PET/CTStatus unknownNCT04125511Lead sponsorEarly phase 1Start 2019-11
  12. Leflunomide Treatment for IgG4-RDStatus unknownNCT03715699Lead sponsorN/AStart 2018-07
  13. Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and/or Immunoglobulin G4-related Sclerosing Cholangitis by CorticosteroidsStatus unknownNCT02797665Lead sponsorN/AStart 2016-05
  14. Study of Treatment Response on IgG4 Related Disease (IgG4RD)Status unknownNCT02458196Lead sponsorPhase 2Start 2015-04
  15. 18F-FDG PET/CT for IgG4-Related DiseaseStatus unknownNCT01665196Lead sponsorEarly phase 1Start 2012-09
  16. Glucocorticoids in Patients With IgG4-RDStatus unknownNCT01758393Lead sponsorPhase 2/Phase 3Start 2012-12
  17. Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung InvolvementNot yet recruitingNCT07806045Lead (inferred)Early phase 1Start 2026-10
  18. A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RDRecruitingNCT07104058Lead (inferred)N/AStart 2025-05
  19. Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RDStatus unknownNCT05781516Lead (inferred)N/AStart 2023-01
  20. Short-term Glucocorticoid Combined with MMF for IgG4-RDStatus unknownNCT06663618Lead (inferred)N/AStart 2023-09
  21. To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild SymptomStatus unknownNCT03368274Lead (inferred)Phase 4Start 2017-09
  22. Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related DiseaseRecruitingNCT07061938Study sitePhase 1/Phase 2Start 2026-01
  23. Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RDNot yet recruitingNCT07222553Study sitePhase 2Start 2026-10
  24. A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseActive, not recruitingNCT05662241Study sitePhase 3Start 2023-01
More papers found outside PubMed (not counted)16
  1. ABS0650 ECONOMIC BURDEN AND LIFE QUALITY OF IgG4-RELATED DISEASE IN CHINA: A COMPARATIVE ANALYSIS OF THREE TREATMENT REGIMENS2025Annals of the Rheumatic Diseasesconference-abstract
  2. ABS0877 FEATURES OF IgG4-RELATED SCLEROSING MESENTERITIS: DATA FROM A LARGE COHORT IN CHINA2025Annals of the Rheumatic Diseasesconference-abstract
  3. Malignancies and IgG4‐related disease2025Rheumatology & autoimmunityarticle
  4. OP0187 THE CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME OF SEROLOGICALLY ACTIVE CLINICALLY QUIESCENT IGG4-RELATED DISEASE: A RETROSPECTIVE STUDY2025Annals of the Rheumatic Diseasesconference-abstract
  5. OP0189 SAFETY AND EFFICACY OF INEBILIZUMAB IN IgG4-RELATED DISEASE ACROSS VARIOUS PARTICIPANT DEMOGRAPHICS: SUBGROUP ANALYSIS FROM THE MITIGATE STUDY2025Annals of the Rheumatic Diseasesconference-abstract
  6. POS0009 Early Onset and Durability of Efficacy in Inebilizumab-treated Participants with IgG4 Related Disease: Post Hoc Analyses from the Phase 3 MITIGATE Trial2025Annals of the Rheumatic Diseasesconference-abstract
  7. POS0647 ASSOCIATION OF TREATING STRATEGY ADJUSTMENT FOR IgG4-RD RELAPSE AND RECURRENT RELAPSE: LESSONS FROM A PROSPECTIVE COHORT2025Annals of the Rheumatic Diseasesconference-abstract
  8. Safety and efficacy of inebilizumab in IgG4 related disease in participants with pancreatic and biliary involvement: Results from the phase 3 mitigate trial2025Pancreatologyarticle
  9. Single-cell multi-omics analysis revealed the expansion of age-associated B cells in the pancreas of type 1 autoimmune pancreatitis patients2025Figsharesupplementary-materials
  10. CT findings of IgG4-related thoracic disease: correlations with clinical and laboratory characteristics2024European Respiratory Journalconference-abstract
  11. Comparison of clinical and radiological features of lung involvement between IgG4-related disease and idiopathic multicentric Castleman disease2024European Respiratory Journalconference-abstract
  12. IgG4-Related Disease2023Springer eBooksbook-chapter
  13. Integrative analysis reveals the role of THBS1 in IgG4-related disease2023Research Squarepreprint
  14. Additional file 3 of TSLP promoting B cell proliferation and polarizing follicular helper T cell as a therapeutic target in IgG4-related disease2022Figsharedataset
  15. Biliary candidiasis mimicking IgG4‐related disease in a patient with normal immunity2022Rheumatology & autoimmunityarticle
  16. Interpretation of Chinese expert consensus on the diagnosis and treatment of IgG4-related diseases2021DOAJ (DOAJ: Directory of Open Access Journals)article

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 6 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 1.2%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 2220232024: 1120242025: 002025

11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

  2. Recruiting
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06463587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesThymus & thymectomyAntibodies & diagnosis
Departments in papersNeurology
Papers it led6
  1. Comorbidity of Myasthenia gravis and Graves' disease as immune reconstitution-associated autoimmune disease in HIV infection: A case report and literature review.2024HIV medicine
  2. Iron metabolism in non-anemic myasthenia gravis patients: A cohort study.2023Journal of neuroimmunology
  3. Combined effect of thymectomy on myasthenia gravis in patients with concomitant auto-immune diseases: a 22-year single-center experience.2023Updates in surgeryFree full text
  4. Severe complications and management of a patient with myasthenia gravis undergoing anterior cervical spinal surgery: a case report.2022Annals of palliative medicine
  5. Differential Expression of miRNA in the Peripheral Blood Mononuclear Cells in Myasthenia Gravis with Muscle-Specific Receptor Tyrosine Kinase Antibodies.2021Critical reviews in eukaryotic gene expression
  6. Surgical treatment is effective in treating thymoma accompanied with non-myasthenia gravis autoimmune diseases: a single-center clinical experience.2021Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society
All its trials on ClinicalTrials.gov, any status4
  1. A Prospective Cohort Study of Myasthenia Gravis in ChinaStatus unknownNCT06006832Lead sponsorStart 2023-08
  2. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  3. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RecruitingNCT06463587Study sitePhase 3Start 2024-06
  4. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisActive, not recruitingNCT05070858Study sitePhase 3Start 2021-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 9 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 2.5%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 882025

8 hospitals in Beijing for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesGeneticsImaging & blood flow
Departments in papersNeurologyNeurosurgeryRadiology / nuclear medicine
Papers it led9
  1. Combining machine learning with external validation to explore necroptosis and immune response in moyamoya disease.2025BMC immunologyFree full text
  2. Construction and Analysis of Immune Infiltration and Competing Endogenous RNA Network in Moyamoya Disease.2025International journal of molecular sciencesFree full text
  3. Recent Advances in Genetics of Moyamoya Disease: Insights into the Different Pathogenic Pathways.2025International journal of molecular sciencesFree full text
  4. Correlation between collateral compensation of the posterior cerebral artery on 5 T magnetic resonance imaging and clinical classifications in patients with Moyamoya angiopathy.2025Japanese journal of radiology
  5. 5.0T MRA techniques for evaluating Moyamoya disease: 4D-ASL-MRA vs. 3D-TOF-MRA.2025Journal of neuroradiology = Journal de neuroradiologie
  6. Single-Cell Transcriptome Profiling Reveals Dynamic Cell Populations and Immune Infiltration in Moyamoya Disease.2025Journal of the American Heart AssociationFree full text
  7. Angiogenesis-related genes and immune microenvironment in moyamoya disease: a transcriptomic and functional analysis.2025Orphanet journal of rare diseasesFree full text
  8. Machine learning identifies KRT8 dysregulation and endothelial remodeling in Moyamoya disease.2025Scientific reportsFree full text
  9. RNF213 in moyamoya disease: Genotype-phenotype association and the underlying mechanism.2024Chinese medical journalFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya SyndromeRecruitingNCT07894107Study siteStart 2026-08
More papers found outside PubMed (not counted)3
  1. Abstract TP382: Genome-wide DNA Methylation Profiling Reveals Low Methylation Variability in Moyamoya Disease2025Strokeconference-abstract
  2. RNA methylation-driven molecular subtypes and immune infiltration in Moyamoya disease2024Gene Reportsarticle
  3. Correlation Analysis of Middle Cerebral Artery Stenosis and Enlarged Perivascular Space in Patients with Moyamoya Disease (S45.007)2023Neurologyarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 3 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

13 hospitals in Beijing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led3
  1. Abundant infiltration of B cells and plasma cells in brain biopsy of a male patient with severe anti-NMDA receptor encephalitis: A case report.2023Medicine
  2. Anti-N-methyl-D-aspartate receptor encephalitis: characteristics and rapid diagnostic approach in the emergency department.2022BMC neurology
  3. The changing spectrum of antibody-mediated encephalitis in China.2021Journal of neuroimmunology
Earlier papers (2016–2020)12
  1. Electroencephalogram and Clinical Characteristics and Correlations in Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis.2020Clinical EEG and neuroscience
  2. Anti-NMDAR encephalitis: A single-center, longitudinal study in China.2020Neurology(R) neuroimmunology & neuroinflammation
  3. [Neuropsychiatric symptoms and caregivers' distress in anti-N-methyl-D-aspartate receptor encephalitis].2020Zhonghua yi xue za zhi
  4. Surgical outcomes in patients with anti-N-methyl D-aspartate receptor encephalitis with ovarian teratoma.2019American journal of obstetrics and gynecology
  5. Nursing care in anti-N-methyl-D-aspartate receptor encephalitis: A case series.2019Medicine
  6. Utility and Safety of Intrathecal Methotrexate Treatment in Severe Anti-N-methyl-D-aspartate Receptor Encephalitis: A Pilot Study.2018Chinese medical journal
  7. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.2018Multiple sclerosis and related disorders
  8. Resection of melanocytic nevi as a potential treatment of anti-NMDAR encephalitis patients without tumor: report of three cases.2018Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  9. [Analysis of prodromal phase and prodromal events in anti-N-methyl-D-aspartate receptor encephalitis].2017Zhonghua yi xue za zhi
  10. Treatment principles of ovarian teratoma with anti-N-methyl-D-aspartate receptor encephalitis.2016Archives of gynecology and obstetrics
  11. Changing Brain Metabolism Patterns in Patients With ANMDARE: Serial 18F-FDG PET/CT Findings.2016Clinical nuclear medicine
  12. [Immunotherapy strategy for 35 cases of severe anti-N-methyl-D-aspartate receptor encephalitis].2016Zhonghua yi xue za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 27 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 14.4%.

Papers led
27
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 2220222023: 7720232024: 7720242025: 662025

30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunologyRadiology / nuclear medicinePediatricsPathology / laboratory medicine
Papers it led27
  1. Mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for treatment of Takayasu arteritis.2025Annals of the rheumatic diseasesRCT
  2. Exosome miR-199a-5p modulated vascular remodeling and inflammatory infiltration of Takayasu's arteritis.2025Arthritis research & therapy
  3. Optimizing ultrasound evaluation of carotid artery stenosis in Takayasu's Arteritis: a focus on residual inner diameter as a key parameter.2025Clinical rheumatology
  4. Downregulated Expression of miR-200c-3p in Plasma Exosome as a Potential Biomarker in Takayasu's Arteritis.2025International journal of molecular sciences
  5. Validation and clinical application of 2022 ACR/EULAR criteria for Takayasu arteritis in a large Chinese cohort.2025Rheumatology (Oxford, England)
  6. Predictors of Cardiovascular Events in Patients With Takayasu Arteritis.2025The Canadian journal of cardiology
  7. Association between premature vascular smooth muscle cells senescence and vascular inflammation in Takayasu's arteritis.2024Annals of the rheumatic diseases
  8. Phenotype of Takayasu-like vasculitis and cardiopathy in patients with Blau syndrome.2024Clinical rheumatology
  9. Incidence, risk factors for active tuberculosis infection and changes of IGRA in patients with Takayasu arteritis: a prospective cohort study.2024Emerging microbes & infections
  10. Serum IL-6 level trajectory for predicting the effectiveness and safety of tocilizumab in the treatment of refractory Takayasu arteritis.2024European journal of internal medicine
  11. A Glimpse into Humoral Response and Related Therapeutic Approaches of Takayasu's Arteritis.2024International journal of molecular sciences
  12. Dark-Blood Computed Tomography Angiography Combined With Deep Learning Reconstruction for Cervical Artery Wall Imaging in Takayasu Arteritis.2024Korean journal of radiology
  13. Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre.2024RMD open
  14. Comparative Efficacy of Secukinumab Versus Tumor Necrosis Factor Inhibitors for the Treatment of Takayasu Arteritis.2023Arthritis & rheumatology (Hoboken, N.J.)
  15. The performance of duplex ultrasonography for the assessment of renal artery stenosis in Takayasu's arteritis patients.2023Arthritis research & therapy
  16. Percutaneous transluminal pulmonary angioplasty for Takayasu arteritis-associated pulmonary hypertension: A single-arm meta-analysis.2023Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  17. Predictors of relapse in Takayasu arteritis.2023European journal of internal medicine
  18. Altered glycosylation profiles of serum IgG in Takayasu arteritis.2023European journal of medical research
  19. Isolated Coronary Arteritis in Adults: a Single-Center Experience from China.2023Journal of cardiovascular translational research
  20. Ultrasonography and contrast-enhanced ultrasound for activity assessment in 115 patients with carotid involvement of Takayasu arteritis.2023Modern rheumatology
  21. Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension.2022Journal of the American College of Cardiology
  22. Pregnancy outcomes in Takayasu arteritis patients.2022Seminars in arthritis and rheumatism
  23. Using the co-expression network of T cell-activation-related genes to assess the disease activity in Takayasu's arteritis patients.2021Arthritis research & therapy
  24. Clinical features and survival in Takayasu's arteritis-associated pulmonary hypertension: a nationwide study.2021European heart journal
  25. Identification of the Association Between Toll-Like Receptors and T-Cell Activation in Takayasu's Arteritis.2021Frontiers in immunology
  26. Clinical Features and Risk Factors for Active Tuberculosis in Takayasu Arteritis: A Single-Center Case-Control Study.2021Frontiers in immunology
  27. Identification of Novel Serological Autoantibodies in Takayasu Arteritis Patients Using HuProt Arrays.2021Molecular & cellular proteomics : MCP
Chinese-language papers (not in the count)4
  1. [Correlation between soluble CD146 and systemic vasculitis].2025Zhonghua nei ke za zhi
  2. [To improve the prognosis in patients with Takayasu's arteritis by standardized the diagnosis and treatment in China].2024Zhonghua nei ke za zhi
  3. [Analysis of differentially expressed microRNA and protein expression profiles carried by exosomes in the plasma of patients with Takayasu's arteritis].2023Zhonghua nei ke za zhi
  4. [Recommendations of diagnosis and treatment of Takayasu's arteritis in China].2022Zhonghua nei ke za zhi
Earlier papers (2016–2020)23
  1. An Observational Study of Sex Differences in Takayasu Arteritis in China: Implications for Worldwide Regional Differences.2020Annals of vascular surgery
  2. Association between acute phase reactants, interleukin-6, tumor necrosis factor-α, and disease activity in Takayasu's arteritis patients.2020Arthritis research & therapy
  3. Impact of coronary involvement on long-term outcomes in patients with Takayasu's arteritis.2020Clinical and experimental rheumatology
  4. Contrast-enhanced ultrasound for evaluating arteritis activity in Takayasu arteritis patients.2020Clinical rheumatology
  5. Response to letter to the editor on "Percutaneous coronary intervention underperforms in Takayasu Arteritis".2020International journal of cardiology
  6. Comparing the effects of different management strategies on long-term outcomes for significant coronary stenosis in patients with Takayasu arteritis.2020International journal of cardiology
  7. Tofacitinib in patients with refractory Takayasu's arteritis.2020Rheumatology (Oxford, England)
  8. Takayasu Arteritis With Coronary Artery Involvement: Differences Between Pediatric and Adult Patients.2020The Canadian journal of cardiology
  9. Pulmonary artery involvement in Takayasu's arteritis: diagnosis before pulmonary hypertension.2019BMC pulmonary medicine
  10. Study on the association of serum pentraxin-3 and lysosomal-associated membrane protein-2 levels with disease activity in Chinese Takayasu's arteritis patients.2019Clinical and experimental rheumatology
  11. Diffuse aortoiliac occlusion with formation of extensive collateral circulation in Takayasu's arteritis.2019European heart journal
  12. The octopus on a heart.2019European heart journal
  13. Tuberculosis Infection in Chinese Patients with Giant Cell Arteritis.2019Scientific reports
  14. Association between genetic variants in the human leukocyte antigen-B/MICA and Takayasu arteritis in Chinese Han population.2018International journal of rheumatic diseases
  15. The renal artery is involved in Chinese Takayasu's arteritis patients.2018Kidney international
  16. [The clinical characteristics of Takayasu's arteritis with glomerulonephropathy].2018Zhonghua nei ke za zhi
  17. The clinical characteristics of Chinese Takayasu's arteritis patients: a retrospective study of 411 patients over 24 years.2017Arthritis research & therapy
  18. The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis.2017Clinical and experimental rheumatology
  19. Takayasu arteritis presented with acute heart failure: case report and review of literature.2017ESC heart failure
  20. Association of FCGR2A/FCGR3A variant rs2099684 with Takayasu arteritis in the Han Chinese population.2017Oncotarget
  21. Single nucleotide polymorphisms of IL12B are associated with Takayasu arteritis in Chinese Han population.2017Rheumatology international
  22. Cause of death in Chinese Takayasu arteritis patients.2016Medicine
  23. The efficacy of Mycophenolate mofetil for the treatment of Chinese Takayasu's arteritis.2016Scientific reports
All its trials on ClinicalTrials.gov, any status6
  1. Pulmonary Artery Involvement in Takayasu's ArteritisCompletedNCT03189602Lead sponsorStart 2014-01
  2. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Study sitePhase 4Start 2026-04
  3. The Efficacy and Safety of Deucravacitinib in Takayasu's ArteritisNot yet recruitingNCT07013838Study sitePhase 4Start 2025-06
  4. Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's ArteritisStatus unknownNCT05749666Study sitePhase 3Start 2023-01
  5. Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's ArteritisCompletedNCT03096275Study sitePhase 3Start 2017-03
  6. American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic VasculitisStatus unknownNCT01066208Study siteStart 2011-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led no English-language PubMed papers on hepatic echinococcosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Beijing for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Ex Vivo Liver Resection and Autotransplantation for End-Stage Alveolar Echinococcosis: A Case Series.2016American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 18 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.8%.

Papers led
18
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 4420212022: 4420222023: 2220232024: 4420242025: 442025

27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

  2. Recruiting
    SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 2/Phase 3
    Started
    2023-06
    Registry
    NCT06125327

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led18
  1. Clinical significance of anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonia: a retrospective observational study.2025BMC pulmonary medicine
  2. Clinical analysis of patients with idiopathic pulmonary fibrosis concurrent with surgery resectable lung cancer: a retrospective cohort study from perspective of ILD physicians.2025BMC pulmonary medicine
  3. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial.2025Nature medicineRCT
  4. Hypertension in idiopathic pulmonary fibrosis: evidence of immune and genetic links from clinical and genomic analyses.2025Respiratory research
  5. Transcriptomic and network analysis identifies shared and unique pathways and immune changes across fibrotic interstitial lung diseases.2024Aging
  6. The immune mechanisms of acute exacerbations of idiopathic pulmonary fibrosis.2024Frontiers in immunology
  7. Tacrolimus alleviates pulmonary fibrosis progression through inhibiting the activation and interaction of ILC2 and monocytes.2024International immunopharmacology
  8. Interstitial lung diseases associated with ANCA positivity: A different disease spectrum from interstitial pneumonia with autoimmune features.2024Respiratory medicine and research
  9. FSTL1 promotes alveolar epithelial cell aging and worsens pulmonary fibrosis by affecting SENP1-mediated DeSUMOylation.2023Cell biology international
  10. Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment.2023Clinical and experimental medicine
  11. SENP1 regulates the transformation of lung resident mesenchymal stem cells and is associated with idiopathic pulmonary fibrosis progression.2022Cell communication and signaling : CCS
  12. Tacrolimus ameliorates bleomycin-induced pulmonary fibrosis by inhibiting M2 macrophage polarization via JAK2/STAT3 signaling.2022International immunopharmacology
  13. Endoplasmic reticulum stress modulates the fate of lung resident mesenchymal stem cell to myofibroblast via C/EBP homologous protein during pulmonary fibrosis.2022Stem cell research & therapy
  14. CCAAT/enhancer-binding protein (C/EBP) homologous protein promotes alveolar epithelial cell senescence via the nuclear factor-kappa B pathway in pulmonary fibrosis.2022The international journal of biochemistry & cell biology
  15. Regulation of the IGF1 signaling pathway is involved in idiopathic pulmonary fibrosis induced by alveolar epithelial cell senescence and core fucosylation.2021Aging
  16. Pulmonary fibrosis in dyskeratosis congenita: a case report with a PRISMA-compliant systematic review.2021BMC pulmonary medicine
  17. Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody.2021BMC pulmonary medicine
  18. Whole-exome sequencing identifies susceptibility genes and pathways for idiopathic pulmonary fibrosis in the Chinese population.2021Scientific reports
Chinese-language papers (not in the count)5
  1. [Recomment of the correctly understand and standardize the use of terms and concepts related to interstitial lung disease].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  2. [Update in interstitial lung disease 2024].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  3. [Update in interstitial lung disease 2023].2024Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  4. [Clinical analysis of autoimmune diseases associated with interstitial lung diseases initially presented with idiopathic pulmonary fibrosis].2022Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  5. [Update in interstitial lung disease 2021].2022Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Earlier papers (2016–2020)12
  1. The Association Between MUC5B Mutations and Clinical Outcome in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Retrospective Exploratory Study in China.2020Medical science monitor : international medical journal of experimental and clinical research
  2. Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice.2020PloS one
  3. Relation between sex hormones and leucocyte telomere length in men with idiopathic pulmonary fibrosis.2020Respirology (Carlton, Vic.)
  4. Clinicopathological characteristics of lung cancer in patients with systemic sclerosis.2020The clinical respiratory journal
  5. [The clinical features and prognosis of interstitial lung disease patients with positive anti-neutrophil cytoplasmic antibody].2020Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  6. Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis.2019Advances in therapyRCT
  7. [The clinical experience of pirfenidone based on corticosteroids and immunosuppressant treatment for interstitial pneumonia with autoimmune features].2019Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  8. [The role of histone deacetylases in the pathogenesis of idiopathic pulmonary fibrosis and cryptogenic organizing pneumonia].2019Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  9. [The role of B cell activating factor in the differential diagnosis of usual interstitial pneumonia].2018Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  10. A CARE-compliant case report: Lung transplantation for a Chinese young man with idiopathic pleuroparenchymal fibroelastosis.2017Medicine
  11. Association between nonspecific interstitial pneumonia and presence of CD20+ B lymphocytes within pulmonary lymphoid follicles.2017Scientific reports
  12. Organizing pneumonia components in non-specific interstitial pneumonia (NSIP): a clinicopathological study of 33 NSIP cases.2016Histopathology
All its trials on ClinicalTrials.gov, any status19
  1. 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary FibrosisStatus unknownNCT02485886Lead sponsorEarly phase 1Start 2015-01
  2. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  3. SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT06125327Study sitePhase 2/Phase 3Start 2023-06
  4. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  5. Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary FibrosisCompletedNCT06764862Study sitePhase 2Start 2025-01
  6. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  7. A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06081621Study sitePhase 2Start 2023-12
  8. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  9. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10
  10. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  11. Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001CompletedNCT05657184Study sitePhase 1Start 2021-07
  12. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04594707Study sitePhase 3Start 2021-08
  13. A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT04419506Study sitePhase 2Start 2020-07
  14. Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary FibrosisCompletedNCT04312594Study sitePhase 2Start 2020-09
  15. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT04419558Study sitePhase 3Start 2020-09
  16. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06
  17. Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)Status unknownNCT01504334Study sitePhase 2Start 2012-01
  18. Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary FibrosisCompletedNCT01619085Study sitePhase 3Start 2012-06
  19. Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01170065Study sitePhase 2Start 2010-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 14 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 31.1%.

Papers led
14
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 2220222023: 1120232024: 3320242025: 332025

5 hospitals in Beijing for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led14
  1. Increased malignancy risk in patients with lymphangioleiomyomatosis: findings from a Chinese cohort.2025Orphanet journal of rare diseases
  2. Associations of VEGF-D levels with clinical manifestations in lymphangioleiomyomatosis: a cross-sectional analysis of 631 cases.2025Orphanet journal of rare diseases
  3. Synergistic effects of mTOR inhibitors with VEGFR3 inhibitors on the interaction between TSC2-mutated cells and lymphatic endothelial cells.2025Science China. Life sciences
  4. Omics research in lymphangioleiomyomatosis: status and challenges.2024Expert review of respiratory medicine
  5. Intraoperative mechanical ventilation and incidence of pneumothorax in lymphangioleiomyomatosis.2024Orphanet journal of rare diseases
  6. Sporadic lymphangioleiomyomatosis in a man with somatic mosaicism of TSC2 mutations, a case report.2024QJM : monthly journal of the Association of Physicians
  7. Determinants of Progression and Mortality in Lymphangioleiomyomatosis.2023Chest
  8. Gene mutations in sporadic lymphangioleiomyomatosis and genotype-phenotype correlation analysis.2022BMC pulmonary medicine
  9. Sirolimus reduces the risk of pneumothorax recurrence in patients with lymphangioleiomyomatosis: a historical prospective self-controlled study.2022Orphanet journal of rare diseases
  10. Lymphangioleiomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex.2021Annals of the American Thoracic Society
  11. The value of transbronchial lung biopsy in the diagnosis of lymphangioleiomyomatosis.2021BMC pulmonary medicine
  12. 68Ga-NOTA-Evans Blue PET/CT findings in lymphangioleiomyomatosis compared with 99mTC-ASC lymphoscintigraphy: a prospective study.2021Orphanet journal of rare diseases
  13. The etiology of diffuse cystic lung diseases: an analysis of 1010 consecutive cases in a LAM clinic.2021Orphanet journal of rare diseases
  14. Pregnancy after the diagnosis of lymphangioleiomyomatosis (LAM).2021Orphanet journal of rare diseases
Earlier papers (2016–2020)13
  1. Lymphangioleiomyomatosis revealed by 68Ga-NOTA-Evans Blue PET/CT.2020European journal of nuclear medicine and molecular imaging
  2. Usefulness of 99mTc-ASC lymphoscintigraphy and SPECT/CT in the evaluation of rare lymphatic disorders: Gorham-Stout disease, lymphangioma, and lymphangioleiomyomatosis.2020Medicine
  3. Effects of yoga on exercise capacity in patients with lymphangioleiomyomatosis: a nonrandomized controlled study.2020Orphanet journal of rare diseases
  4. Kaposiform lymphangiomatosis with spinal involvement.2020QJM : monthly journal of the Association of Physicians
  5. Lymphangioleiomyomatosis.2020Seminars in respiratory and critical care medicine
  6. Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome.2019Chinese medical journal
  7. Clinical characteristics in lymphangioleiomyomatosis-related pulmonary hypertension: an observation on 50 patients.2019Frontiers of medicine
  8. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.2019Orphanet journal of rare diseases
  9. The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.2018Orphanet journal of rare diseases
  10. Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.2018Orphanet journal of rare diseases
  11. Rapamycin for lymphangioleiomyomatosis: optimal timing and optimal dosage.2018Thorax
  12. Coexistence of pulmonary lymphangioleiomyomatosis and pulmonary angiomyolipoma.2016BMC pulmonary medicine
  13. Diffuse Cystic Lung Diseases: Diagnostic Considerations.2016Seminars in respiratory and critical care medicine
All its trials on ClinicalTrials.gov, any status2
  1. Characterizing LAM With 11C-Choline PET/CTStatus unknownNCT05087134Lead sponsorEarly phase 1Start 2021-11
  2. A National Registry on Chinese Patients With LymphangioleiomyomatosisStatus unknownNCT03193892Lead sponsorStart 2017-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 44 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 5.7%.

Papers led
44
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 171720222023: 5520232024: 9920242025: 552025

19 hospitals in Beijing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led44
  1. Impacts of oral supplementation of vitamin B12 and plasma levels of homocysteine on progression and survival in a Chinese ALS cohort.2026Neurological research
  2. Gain-of-function ANXA11 mutation cause late-onset ALS with aberrant protein aggregation, neuroinflammation and autophagy impairment.2025Acta neuropathologica communications
  3. Exploring oculomotor challenges in amyotrophic lateral sclerosis: a comprehensive review.2025Amyotrophic lateral sclerosis & frontotemporal degeneration
  4. The Impact of Bulbar and Upper Motor Neuron Involvement on Oculomotor Movement in Amyotrophic Lateral Sclerosis.2025Brain and behavior
  5. Lead exposure induces ferroptosis in ALS cell models by activating the MAPK/ERK signaling pathway.2025Ecotoxicology and environmental safety
  6. Fasciculation in limbs serves as the predictor of ALS progression: an ultrasound study.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  7. The Inflammatory Puzzle: Piecing together the Links between Neuroinflammation and Amyotrophic Lateral Sclerosis.2024Aging and disease
  8. Genotype-phenotype association and functional analysis of hnRNPA1 mutations in amyotrophic lateral sclerosis.2024Amyotrophic lateral sclerosis & frontotemporal degeneration
  9. Neuromuscular ultrasound in combination with nerve conduction studies helps identify inflammatory motor neuropathies from lower motor neuron syndromes.2024European journal of neurology
  10. Dysregulated N6-methyladenosine modification in peripheral immune cells contributes to the pathogenesis of amyotrophic lateral sclerosis.2024Frontiers of medicine
  11. Clinical and genetic characteristics of 1672 cases of amyotrophic lateral sclerosis in China: a single-center retrospective study.2024Journal of neurology
  12. The prognostic value of systematic genetic screening in amyotrophic lateral sclerosis patients.2024Journal of neurology
  13. Development of novel treatments for amyotrophic lateral sclerosis.2024Metabolic brain disease
  14. Incidence of amyotrophic lateral sclerosis-associated genetic variants: a clinic-based study.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  15. Split Phenomenon of Fasciculation between Antagonistic Muscles in Amyotrophic Lateral Sclerosis: An Ultrasound Study.2024The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  16. Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study.2023Brain and behavior
  17. The Serotonergic System and Amyotrophic Lateral Sclerosis: A Review of Current Evidence.2023Cellular and molecular neurobiology
  18. A multicenter, randomized, double blind, placebo-controlled clinical trial of DL-3-n-butylphthalide in treatment of amyotrophic lateral sclerosis.2023Chinese medical journalRCT
  19. The cross-sectional area of peripheral nerve in amyotrophic lateral sclerosis: A case-control study.2023Clinical neurology and neurosurgery
  20. The level of homocysteine in amyotrophic lateral sclerosis: a systematic review and meta-analysis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  21. The frequency of ALSFRS-R reversals and plateaus in patients with limb-onset amyotrophic lateral sclerosis: a cohort study.2022Acta neurologica Belgica
  22. Association of apolipoprotein E ε4 allele and amyotrophic lateral sclerosis in Chinese population.2022Amyotrophic lateral sclerosis & frontotemporal degeneration
  23. Slow progression of amyotrophic lateral sclerosis in a Chinese patient carrying SOD1 p.S135T mutation.2022Amyotrophic lateral sclerosis & frontotemporal degeneration
  24. Alterations in metabolic biomarkers and their potential role in amyotrophic lateral sclerosis.2022Annals of clinical and translational neurology
  25. Brain structural and perfusion changes in amyotrophic lateral sclerosis-frontotemporal dementia patients with cognitive and motor onset: a preliminary study.2022Brain imaging and behavior
  26. Association between abnormal expression and methylation of LGALS1 in amyotrophic lateral sclerosis.2022Brain research
  27. Epigenome-wide DNA methylation study of whole blood in patients with sporadic amyotrophic lateral sclerosis.2022Chinese medical journal
  28. Plateaus and reversals evaluated by different methods in patients with limb-onset amyotrophic lateral sclerosis.2022Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  29. Cardiovascular comorbidities in amyotrophic lateral sclerosis: A systematic review.2022Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  30. Genotype-phenotype association of TARDBP mutations in Chinese patients with amyotrophic lateral sclerosis: a single-center study and systematic review of published literature.2022Journal of neurology
  31. Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells.2022Molecular neurodegeneration
  32. Survival analysis of clinical and genetic factors in an amyotrophic lateral sclerosis cohort from China.2022Neurological research
  33. Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  34. Blood-brain barrier dysfunction and myelin basic protein in survival of amyotrophic lateral sclerosis with or without frontotemporal dementia.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  35. Mutation spectrum of chinese amyotrophic lateral sclerosis patients with frontotemporal dementia.2022Orphanet journal of rare diseases
  36. Clinical characteristics and prognosis of amyotrophic lateral sclerosis with autoimmune diseases.2022PloS one
  37. Correlation of weight and body composition with disease progression rate in patients with amyotrophic lateral sclerosis.2022Scientific reports
  38. Mutations of DNAJC7 are rare in Chinese amyotrophic lateral sclerosis patients.2021Amyotrophic lateral sclerosis & frontotemporal degeneration
  39. Fasciculation differences between ALS and non-ALS patients: an ultrasound study.2021BMC neurology
  40. Split hand in amyotrophic lateral sclerosis: A systematic review and meta-analysis.2021Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  41. Authors' reply: Four novel optineurin mutations in patients with sporadic amyotrophic lateral sclerosis in Mainland China.2021Neurobiology of aging
  42. Four novel optineurin mutations in patients with sporadic amyotrophic lateral sclerosis in Mainland China.2021Neurobiology of aging
  43. Split phenomenon of antagonistic muscle groups in amyotrophic lateral sclerosis: relative preservation of flexor muscles.2021Neurological research
  44. The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population.2021Translational neurodegeneration
Chinese-language papers (not in the count)2
  1. [Attention should be paid to the importance of genetic testing in clinical practice of amyotrophic lateral sclerosis].2023Zhonghua yi xue za zhi
  2. [Prospects and problems of using genetic tests for clinical practice of amyotrophic lateral sclerosis].2021Zhonghua nei ke za zhi
Earlier papers (2016–2020)28
  1. A prospective study on split-hand index as a biomarker for the diagnosis of amyotrophic lateral sclerosis.2020Amyotrophic lateral sclerosis & frontotemporal degeneration
  2. Strategy for screening cognitive impairment in Chinese patients with amyotrophic lateral sclerosis.2020Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  3. Split-hand index in amyotrophic lateral sclerosis: an F-wave study.2019Amyotrophic lateral sclerosis & frontotemporal degeneration
  4. Study on variation trend of repetitive nerve stimulation waveform in amyotrophic lateral sclerosis.2019Chinese medical journal
  5. Triple Stimulation Technique in Amyotrophic Lateral Sclerosis.2019Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
  6. Early onset but long survival and other prognostic factors in Chinese sporadic amyotrophic lateral sclerosis.2019Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  7. Environmental risk factors and amyotrophic lateral sclerosis (ALS): A case-control study of ALS in China.2019Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  8. Mutation analysis of KIF5A in Chinese amyotrophic lateral sclerosis patients.2019Neurobiology of aging
  9. Monitoring Value of Multimodal Magnetic Resonance Imaging in Disease Progression of Amyotrophic Lateral Sclerosis: A Prospective Observational Study.2018Chinese medical journal
  10. Creatine kinase level and its relationship with quantitative electromyographic characteristics in amyotrophic lateral sclerosis.2018Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  11. Excessive daytime sleepiness in Chinese patients with sporadic amyotrophic lateral sclerosis and its association with cognitive and behavioural impairments.2018Journal of neurology, neurosurgery, and psychiatry
  12. Mutation screening of NEK1 in Chinese ALS patients.2018Neurobiology of aging
  13. Genetic analysis of TIA1 gene in Chinese patients with amyotrophic lateral sclerosis.2018Neurobiology of aging
  14. Screening of GLE1 mutations in Chinese amyotrophic lateral sclerosis patients.2018Neurobiology of aging
  15. [Resting-state functional MRI studies of amyotrophic lateral sclerosis patients with various levels of cognitive impairment].2018Zhonghua yi xue za zhi
  16. Familial Early-Onset Paget's Disease of Bone Associated with a Novel hnRNPA2B1 Mutation.2017Calcified tissue international
  17. Military service and the risk of amyotrophic lateral sclerosis: A meta-analysis.2017Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  18. The Awaji criteria increases the diagnostic sensitivity of the revised El Escorial criteria for amyotrophic lateral sclerosis diagnosis in a Chinese population.2017PloS one
  19. [Sample size for the estimation of F-wave parameters in healthy volunteers and amyotrophic lateral sclerosis patients].2017Zhonghua yi xue za zhi
  20. H46R SOD1 mutation is consistently associated with a relatively benign form of amyotrophic lateral sclerosis with slow progression.2016Amyotrophic lateral sclerosis & frontotemporal degeneration
  21. Screening of the TBK1 gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin.2016Amyotrophic lateral sclerosis & frontotemporal degeneration
  22. Mutations in FUS are the most frequent genetic cause in juvenile sporadic ALS patients of Chinese origin.2016Amyotrophic lateral sclerosis & frontotemporal degeneration
  23. Quantitating Changes in Jitter and Spike Number Using Concentric Needle Electrodes in Amyotrophic Lateral Sclerosis Patients.2016Chinese medical journal
  24. Pattern Differences of Small Hand Muscle Atrophy in Amyotrophic Lateral Sclerosis and Mimic Disorders.2016Chinese medical journal
  25. Mutation spectrum of Chinese patients with familial and sporadic amyotrophic lateral sclerosis.2016Journal of neurology, neurosurgery, and psychiatry
  26. The distinctive genetic architecture of ALS in mainland China.2016Journal of neurology, neurosurgery, and psychiatry
  27. Identification of a novel loss-of-function C9orf72 splice site mutation in a patient with amyotrophic lateral sclerosis.2016Neurobiology of aging
  28. Whole-exome sequencing identifies a missense mutation in hnRNPA1 in a family with flail arm ALS.2016Neurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led 3 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 5.5%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

8 hospitals in Beijing for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07444476

    Age 15 years to 60 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 2 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 2.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

11 hospitals in Beijing for Fabry disease85 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07187440

    Age 7 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led 1 of the 30 English-language PubMed papers on Pompe disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

6 hospitals in Beijing for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

11 hospitals in Beijing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT07058662

    Age 4 years to 9 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurology
Papers it led2
  1. Prevalence of Neutralizing Antibodies Against AAV Serotypes 2 and 9 in Healthy Participants from Multiple Centers Across China and Patients with DMD/BMD.2024Human gene therapy
  2. Identification and characterization of two DMD pedigrees with large inversion mutations based on a long-read sequencing pipeline.2023European journal of human genetics : EJHG
Earlier papers (2016–2020)2
  1. Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.2020Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  2. Exonic rearrangements in DMD in Chinese Han individuals affected with Duchenne and Becker muscular dystrophies.2020Human mutation
All its trials on ClinicalTrials.gov, any status6
  1. A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular DystrophyActive, not recruitingNCT07282652Lead sponsorEarly phase 1Start 2025-12
  2. A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.Active, not recruitingNCT06392724Lead sponsorEarly phase 1Start 2024-07
  3. Bisoprolol in DMD Early CardiomyopathyStatus unknownNCT03779646Lead sponsorPhase 2/Phase 3Start 2019-01
  4. A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.RecruitingNCT07058662Study sitePhase 1/Phase 2Start 2025-07
  5. Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMDTerminatedNCT04632940Study sitePhase 3Start 2021-03
  6. Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)TerminatedNCT04371666Study sitePhase 3Start 2020-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 49 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 20.0%.

Papers led
49
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 9920212022: 111120222023: 111120232024: 7720242025: 992025

24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Baricitinib in the Treatment of Intestinal Behçet's Syndrome
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06849908

    Age 18 years to 65 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  2. Recruiting
    Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05845723

    Age 18 years to 65 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunologyPathology / laboratory medicineOphthalmology / neuro-ophthalmologyGastroenterology / hepatology
Papers it led49
  1. The clinical features, pathological findings, and risk factors of intracardiac thrombus in Behçet's syndrome.2026Clinical rheumatology
  2. Artificial Intelligence-Driven Proteomics Identifies Plasma Protein Signatures for Diagnosis and Stratification of Behçet's Disease.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  3. The efficacy and safety of monoclonal anti-TNF antibodies in the treatment of vascular Behçet's syndrome: A systematic review and meta-analysis.2025Autoimmunity reviews
  4. Neuro-Behçet's disease: an update of clinical diagnosis, biomarkers, and immunopathogenesis.2025Clinical and experimental immunology
  5. Clinicopathological characteristics of severe aortic valve regurgitation caused by Behçet's syndrome.2025Clinical and experimental rheumatology
  6. Evaluation of inflammatory-thrombosis panel as a diagnostic tool for vascular Behçet's disease.2025Clinical rheumatology
  7. Systemic vasculitis with latent tuberculosis infection and associated factors: a cross-sectional multicenter study.2025Clinical rheumatology
  8. Association between COVID-19 infection and uveitis flare in patients with Behcet's disease, a retrospective multicenter cohort study.2025Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  9. Optimal timing of surgical treatment for Behcet's disease aortic or peripheral artery pseudoaneurysms.2025Journal of vascular surgery
  10. Defective neutrophil-derived exosomes facilitate macrophage activation through miR-122-5p in Behçet's disease.2025Nature communications
  11. Quantitative urinary proteome analysis reveals potential biomarkers for disease activity of Behcet's disease uveitis.2024BMC ophthalmology
  12. Significance of immunoglobulins synthesis with central nervous system involvement in Neuro-Behçet's disease.2024Clinica chimica acta; international journal of clinical chemistry
  13. Infliximab for parenchymal neuro-Behçet's syndrome: case series and meta-analysis.2024Clinical and experimental rheumatology
  14. Endovascular repair with a physician-modified fenestrated endograft to treat abdominal aortic pseudoaneurysm with Behcet's disease: a case report.2024Journal of cardiothoracic surgery
  15. TNF inhibitors target a mevalonate metabolite/TRPM2/calcium signaling axis in neutrophils to dampen vasculitis in Behçet's disease.2024Nature communications
  16. Behçet Disease Periaortic Pseudoaneurysms Connect with Pulmonary Artery.2024Radiology
  17. Shelterin dysfunction promotes CD4+ T cell senescence in Behçet's disease.2024Rheumatology (Oxford, England)
  18. Response to: 'Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome'' by Zou et al.2023Annals of the rheumatic diseases
  19. Proteomics Landscape Mapping of Organ-Resolved Behçet's Disease Using In-Depth Plasma Proteomics for Identifying Hyaluronic Binding Protein 2 Expression Associated With Vascular Involvement.2023Arthritis & rheumatology (Hoboken, N.J.)
  20. Giant coronary aneurysm of Behcet's disease with sudden syncope: a case report.2023BMC cardiovascular disorders
  21. Infectious agents and pathogenesis of Behçet's disease: An extensive review.2023Clinical immunology (Orlando, Fla.)
  22. Baricitinib for the treatment of refractory vascular Behçet's disease.2023Clinical immunology (Orlando, Fla.)
  23. Myelin basic protein and index for neuro-Behçet's disease.2023Clinical immunology (Orlando, Fla.)
  24. Baricitinib for the treatment of intestinal Behçet's disease: A pilot study.2023Clinical immunology (Orlando, Fla.)
  25. Long Term Outcomes and Potential Risk Factors for Endovascular Repair of Aortic Pseudoaneurysms in Vascular Behçet's Disease.2023European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
  26. Chemokines and chemokine receptors in Behçet's disease.2023Frontiers in immunology
  27. Integrated analyses delineate distinctive immunological pathways and diagnostic signatures for Behcet's disease by leveraging gene microarray data.2023Immunologic research
  28. Intestinal Behcet's Disease: A Review of the Immune Mechanism and Present and Potential Biological Agents.2023International journal of molecular sciences
  29. Macrophage polarization toward M1 phenotype through NF-κB signaling in patients with Behçet's disease.2022Arthritis research & therapy
  30. Pharyngeal reconstruction for severe pharyngeal stenosis in Behçet's disease: a retrospective case series.2022Clinical and experimental rheumatology
  31. The clinical features, image findings and risk factors of vena cava syndrome in Behçet's syndrome.2022Clinical and experimental rheumatology
  32. Anti-interleukin 6 receptor antibody tocilizumab was not satisfactory for acute attack of Behçet's uveitis in three consecutive patients.2022Clinical and experimental rheumatology
  33. Transcriptional analysis of neutrophils from patients with Behçet's disease reveals activation and chemotaxis of neutrophils.2022Clinical immunology (Orlando, Fla.)
  34. Identification of novel genes in Behcet's disease using integrated bioinformatic analysis.2022Immunologic research
  35. The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta-analysis.2022Journal of gastroenterology and hepatology
  36. Authors Reply to Letter to the Editor - In Response To: Comment on Pei M et al.'s "Analysis of Parafoveal Microvascular Abnormalities in Behcet's Uveitis Using Projection-resolved Optical Coherence Tomographic Angiography".2022Ocular immunology and inflammation
  37. Single-cell analyses highlight the proinflammatory contribution of C1q-high monocytes to Behçet's disease.2022Proceedings of the National Academy of Sciences of the United States of America
  38. Secukinumab in the treatment of parenchymal neuro-Behçet's syndrome.2022Rheumatology (Oxford, England)
  39. Clinical features and prognosis of patients with gastrointestinal Behçet's disease-like syndrome and myelodysplastic syndrome with and without trisomy 8.2022Seminars in arthritis and rheumatism
  40. Comprehensive analysis of immunoglobulin and clinical variables identifies functional linkages and diagnostic indicators associated with Behcet's disease patients receiving immunomodulatory treatment.2021BMC immunology
  41. Increased serum level of interleukin-33 in Vogt-Koyanagi-Harada correlates with disease activity.2021Clinical immunology (Orlando, Fla.)
  42. Aberrant monocyte subsets in patients with Behçet's disease.2021Clinical immunology (Orlando, Fla.)
  43. Variation of red blood cell parameters in Behcet's disease: association with disease severity and vascular involvement.2021Clinical rheumatology
  44. Anaplastic large cell lymphoma in a patient with MAGIC syndrome: a case and review of the literature.2021Clinical rheumatology
  45. Novel Insights Into Gene Signatures and Their Correlation With Immune Infiltration of Peripheral Blood Mononuclear Cells in Behcet's Disease.2021Frontiers in immunology
  46. Genetic Association of Interleukin 33/ST2 Polymorphisms With Behcet's Uveitis.2021Frontiers in immunology
  47. Mucosal healing in intestinal Behçet's disease: A systematic review and meta-analysis.2021Journal of digestive diseases
  48. Analysis of Parafoveal Microvascular Abnormalities in Behcet's Uveitis Using Projection-Resolved Optical Coherence Tomographic Angiography.2021Ocular immunology and inflammation
  49. Neutrophil Extracellular Traps Promote Aberrant Macrophages Activation in Behçet's Disease.2020Frontiers in immunology
Chinese-language papers (not in the count)2
  1. [Myelodysplastic syndrome with trisomy 8 related multiple intestinal ulcers: a case report].2023Zhonghua nei ke za zhi
  2. [Recommendations for the diagnosis and treatment of Behçet's syndrome in China].2021Zhonghua nei ke za zhi
Earlier papers (2016–2020)26
  1. A pilot study of tofacitinib for refractory Behçet's syndrome.2020Annals of the rheumatic diseases
  2. Meta-analysis of anti-Saccharomyces cerevisiae antibodies as diagnostic markers of Behçet's disease with gastrointestinal involvement.2020BMJ open
  3. [Progress in interferon: A treatment of Behcet syndrome].2020Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  4. [Clinical analysis of golimumab in the treatment of severe/refractory cardiovascular involvement in Behcet syndrome].2020Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  5. Behçet's disease and subacute thyroiditis after a rabies inoculation: a case report and review of the literature.2020Clinical and experimental rheumatology
  6. Aberrant FcγRIIb and FcγRIII expression on monocytes from patients with Behçet's disease.2020Clinical immunology (Orlando, Fla.)
  7. Clinical manifestations of Behçet's disease in a large cohort of Chinese patients: gender- and age-related differences.2020Clinical rheumatology
  8. Clinical Features and Risk Factors of Active Tuberculosis in Patients with Behçet's Disease.2020Journal of immunology research
  9. [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].2020Zhonghua nei ke za zhi
  10. [Cardiologists' perceptions on Behcet's disease and its cardiovascular lesions: a single center analysis].2020Zhonghua nei ke za zhi
  11. [Current research on cytokine gene single nucleotide polymorphisms of Behcet's syndrome].2020[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  12. [Clinical features of patients with Behcet's uveitis].2020[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  13. Diagnostic value of the interferon-γ release assay for tuberculosis infection in patients with Behçet's disease.2019BMC infectious diseases
  14. Coronary involvement in patients with Behçet's disease.2019Clinical rheumatology
  15. Erythematous plaques and nodules with orogenital ulcerations.2019Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  16. The Clinical Features, Risk Factors, and Outcome of Aneurysmal Lesions in Behcet's Disease.2019Journal of immunology research
  17. The Clinical Features and Risk Factors of Parenchymal Neuro-Behcet's Disease.2019Journal of immunology research
  18. Metabolomic alterations associated with Behçet's disease.2018Arthritis research & therapy
  19. Expression correlates between Annexin A1 and A2 autoantibodies in patients with Behçet's disease.2018Bioscience reports
  20. Cerebral venous sinus thrombosis in Behçet's disease: a retrospective case-control study.2018Clinical rheumatology
  21. Tocilizumab in the treatment of severe and/or refractory vasculo-Behçet's disease: a single-centre experience in China.2018Rheumatology (Oxford, England)
  22. Preoperative immunosuppressive therapy reduces paravalvular leakage after aortic valve surgery in patients with aortic regurgitation attributable to Behçet's disease.2016Clinical and experimental rheumatology
  23. Intracardiac thrombus in patients with Behcet's disease: clinical correlates, imaging features, and outcome: a retrospective, single-center experience.2016Clinical rheumatology
  24. Association study of rs924080 and rs11209032 polymorphisms of IL23R-IL12RB2 in a Northern Chinese Han population with Behcet's disease.2016Human immunology
  25. Outcomes of vascular intervention and use of perioperative medications for nonpulmonary aneurysms in Behçet disease.2016Surgery
  26. [Behcet's disease and infection].2016[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
All its trials on ClinicalTrials.gov, any status7
  1. Baricitinib in the Treatment of Intestinal Behçet's SyndromeRecruitingNCT06849908Lead sponsorPhase 2Start 2024-11
  2. Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's SyndromeRecruitingNCT05845723Lead sponsorPhase 2Start 2023-06
  3. Pathogenesis of Intestinal Behcet's SyndromeStatus unknownNCT06026020Lead sponsorStart 2023-09
  4. Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease UveitisCompletedNCT03209219Lead sponsorPhase 3Start 2017-06
  5. Golimumab for the Treatment of Refractory Behcet's UveitisTerminatedNCT04218565Lead (inferred)Phase 2Start 2020-02
  6. Tocilizumab for the Treatment of Refractory Behcet's UveitisTerminatedNCT03554161Lead (inferred)Phase 2Start 2018-05
  7. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 5 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.7%.

Papers led
5
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 112025

32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyPathology / laboratory medicine
Papers it led5
  1. New biomarkers in IgA nephropathy.2025Clinical immunology (Orlando, Fla.)
  2. The significance of subclassifying focal segmental glomerulosclerosis lesions (S1) in IgA nephropathy.2024Kidney international
  3. Clinicopathological Features of Gitelman Syndrome with Proteinuria and Renal Dysfunction.2023Nephron
  4. Urinary complement proteins in IgA nephropathy progression from a relative quantitative proteomic analysis.2023PeerJ
  5. The spectrum of kidney biopsy findings in Chinese HIV-infected patients.2022HIV medicine
Earlier papers (2016–2020)11
  1. Serum TNF-α Level Is Associated with Disease Severity in Adult Patients with Immunoglobulin A Vasculitis Nephritis.2020Disease markers
  2. Serum Soluble CD89-IgA Complexes Are Elevated in IgA Nephropathy without Immunosuppressant History.2020Disease markers
  3. [Treatment of IgA nephropathy in the era of evidence-based medicine and personalized medicine].2020Zhonghua yi xue za zhi
  4. Serum Levels of Joining Chain-Containing IgA1 Are Not Elevated in Patients with IgA Nephropathy.2019Disease markers
  5. [The 467th case: proteinuria, periungual fibromas, and facial steatadenomas].2019Zhonghua nei ke za zhi
  6. Serum levels of tumor necrosis factor alpha in patients with IgA nephropathy are closely associated with disease severity.2018BMC nephrology
  7. Diffusional kurtosis imaging in assessing renal function and pathology of IgA nephropathy: a preliminary clinical study.2018Clinical radiology
  8. [The clinical characteristics of Takayasu's arteritis with glomerulonephropathy].2018Zhonghua nei ke za zhi
  9. The Neglected Significance of Glomerular Density as a 5-year Progression Indicator for IgA Nephropathy△.2017Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  10. Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy.2017International urology and nephrology
  11. Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease.2016International urology and nephrology
All its trials on ClinicalTrials.gov, any status1
  1. Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA NephropathyStatus unknownNCT02765594Lead sponsorPhase 4Start 2016-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led 1 of the 30 English-language PubMed papers on Gaucher disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

5 hospitals in Beijing for Gaucher disease41 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsRadiology / nuclear medicine
Papers it led1
  1. Use of IDEAL-IQ in Quantifying Femoral Bone Marrow Involvement in Gaucher Disease.2023Journal of computer assisted tomography
Chinese-language papers (not in the count)1
  1. [Diagnosis and treatment of pediatric Gaucher disease].2023Zhonghua er ke za zhi = Chinese journal of pediatrics
Earlier papers (2016–2020)2
  1. [Quality of life of 22 patients with type 1 Gaucher disease after enzyme replacement therapy].2020Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  2. Gaucher Disease with Mesenteric Lymphadenopathy: A Case with 13-year Follow-up.2016Chinese medical journal
All its trials on ClinicalTrials.gov, any status5
  1. Efficacy and Safety of Eliglustat in Chinese Pediatric Patients With Gaucher Disease Type 1 and Type 3Status unknownNCT06523517Lead sponsorPhase 2Start 2024-08
  2. A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseaseCompletedNCT05529992Study sitePhase 3Start 2023-01
  3. Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3Active, not recruitingNCT05222906Study sitePhase 3Start 2022-04
  4. Phase 1/2 Study of CAN103 in Subjects With Gaucher DiseaseStatus unknownNCT05447494Study sitePhase 1/Phase 2Start 2022-07
  5. A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)CompletedNCT01074944Study sitePhase 3Start 2010-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 14 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 14.1%.

Papers led
14
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 5520222023: 1120232024: 7720242025: 112025

5 hospitals in Beijing for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07557446

    Age 12 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Shanghai, Shenzhen, Suzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led14
  1. TBS as a complementary tool for assessing vertebral fractures and spinal deformity in children and adolescents with osteogenesis imperfecta.2025Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
  2. Correlation of serum DKK1 level with skeletal phenotype in children with osteogenesis imperfecta.2024Journal of endocrinological investigation
  3. Correlation of lipocalin 2 and glycolipid metabolism and body composition in a large cohort of children with osteogenesis imperfecta.2024Journal of endocrinological investigation
  4. Genotype-phenotype relationship and comparison between eastern and western patients with osteogenesis imperfecta.2024Journal of endocrinological investigation
  5. Response to Letter to the Editor From Bala and Dayal: "Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study".2024The Journal of clinical endocrinology and metabolism
  6. Genetic Analysis, Phenotypic Spectrum and Functional Study of Rare Osteogenesis Imperfecta Caused by CRTAP Variants.2024The Journal of clinical endocrinology and metabolism
  7. Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.2024The Journal of clinical endocrinology and metabolismRCT
  8. Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study.2024The Journal of clinical endocrinology and metabolismRCT
  9. Genotypic and Phenotypic Spectrum and Pathogenesis of WNT1 Variants in a Large Cohort of Patients With OI/Osteoporosis.2023The Journal of clinical endocrinology and metabolism
  10. Cardiovascular abnormalities and its correlation with genotypes of children with osteogenesis imperfecta.2022Frontiers in endocrinology
  11. Skeletal outcomes of patients with osteogenesis imperfecta during drug holiday of bisphosphonates: a real-world study.2022Frontiers in endocrinology
  12. The role of osteocalcin in regulation of glycolipid metabolism and muscle function in children with osteogenesis imperfecta.2022Frontiers in endocrinology
  13. Delineation of dual molecular diagnosis in patients with skeletal deformity.2022Orphanet journal of rare diseases
  14. Relationship of Pathogenic Mutations and Responses to Zoledronic Acid in a Cohort of Osteogenesis Imperfecta Children.2022The Journal of clinical endocrinology and metabolism
Earlier papers (2016–2020)16
  1. A novel mutation in PLS3 causes extremely rare X-linked osteogenesis imperfecta.2020Molecular genetics & genomic medicine
  2. A novel missense mutation in P4HB causes mild osteogenesis imperfecta.2019Bioscience reports
  3. Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta.2019Bone
  4. Genotype-phenotype relationship in a large cohort of osteogenesis imperfecta patients with COL1A1 mutations revealed by a new scoring system.2019Chinese medical journal
  5. Novel mutations in BMP1 induce a rare type of osteogenesis imperfecta.2019Clinica chimica acta; international journal of clinical chemistry
  6. Health-related quality of life in children with osteogenesis imperfecta: a large-sample study.2019Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
  7. Novel Mutations in PLOD2 Cause Rare Bruck Syndrome.2018Calcified tissue international
  8. Extremely low level of serum pigment epithelium-derived factor is a special biomarker of Chinese osteogenesis imperfecta patients with SERPINF1 mutations.2018Clinica chimica acta; international journal of clinical chemistry
  9. Novel compound heterozygous mutations in SERPINH1 cause rare autosomal recessive osteogenesis imperfecta type X.2018Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
  10. Novel Mutations in SERPINF1 Result in Rare Osteogenesis Imperfecta Type VI.2017Calcified tissue international
  11. Novel mutations in FKBP10 in Chinese patients with osteogenesis imperfecta and their treatment with zoledronic acid.2017Journal of human genetics
  12. Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing.2017Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
  13. Osteogenesis imperfecta type V: Genetic and clinical findings in eleven Chinese patients.2016Clinica chimica acta; international journal of clinical chemistry
  14. Genotype-phenotype analysis of a rare type of osteogenesis imperfecta in four Chinese families with WNT1 mutations.2016Clinica chimica acta; international journal of clinical chemistry
  15. A cryptic balanced translocation involving COL1A2 gene disruption cause a rare type of osteogenesis imperfecta.2016Clinica chimica acta; international journal of clinical chemistry
  16. Two novel mutations in TMEM38B result in rare autosomal recessive osteogenesis imperfecta.2016Journal of human genetics
All its trials on ClinicalTrials.gov, any status2
  1. A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)RecruitingNCT07557446Study sitePhase 2Start 2026-07
  2. Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaActive, not recruitingNCT05972551Study sitePhase 3Start 2024-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 22 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 7.3%.

Papers led
22
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 6620212022: 3320222023: 3320232024: 6620242025: 442025

16 hospitals in Beijing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Research of Tapering UDCA in PBC Patients With a Complete Response
    Phase
    Phase 4
    Started
    2020-01
    Registry
    NCT04650243

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  2. Recruiting
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    Phase
    Phase 2/Phase 3
    Started
    2023-02
    Registry
    NCT05749822

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan’an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunologyPathology / laboratory medicineGastroenterology / hepatologyNephrology
Papers it led22
  1. Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive.2025Clinical and molecular hepatology
  2. Clinical characteristics of dyslipidemia in patients with primary biliary cholangitis: a single-center experience in China.2025Clinical rheumatology
  3. Postpartum may be a risk factor for biochemical flares in patients with primary biliary cholangitis: A single-center experience.2025Clinical rheumatology
  4. Clinical characteristics of primary biliary cirrhosis - idiopathic inflammatory myopathy overlap syndrome: A single center study.2025The American journal of the medical sciences
  5. Glomerulonephritis in primary biliary cholangitis in China: an important complication.2024Clinical rheumatology
  6. Revisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis.2024Expert opinion on pharmacotherapy
  7. ChIP-seq analysis found IL21R, a target gene of GTF2I-the susceptibility gene for primary biliary cholangitis in Chinese Han.2024Hepatology international
  8. Exploring Advanced Therapies for Primary Biliary Cholangitis: Insights from the Gut Microbiota-Bile Acid-Immunity Network.2024International journal of molecular sciences
  9. Risk of comorbidity of autoimmune liver disease in patients with inflammatory bowel disease: A single-center case-control study in China.2024Journal of digestive diseases
  10. Rare renal proximal tubular dysfunctions in primary biliary cholangitis.2024Renal failure
  11. Genetic predisposition of the gastrointestinal microbiome and primary biliary cholangitis: a bi-directional, two-sample Mendelian randomization analysis.2023Frontiers in endocrinology
  12. Plasma lipidomics of primary biliary cholangitis and its comparison with Sjögren's syndrome.2023Frontiers in immunology
  13. CCL26 in primary biliary cholangitis - Is it a novel disease mediator?2023International journal of rheumatic diseases
  14. Low vitamin D concentrations and BMI are causal factors for primary biliary cholangitis: A mendelian randomization study.2022Frontiers in immunology
  15. Single-Cell Characterization of Hepatic CD8+ T Cells in a Murine Model of Primary Biliary Cholangitis.2022Frontiers in immunology
  16. Imbalanced distribution of group 2 innate lymphoid cells (ILCs) and ILC precursors in peripheral blood of patients with primary biliary cholangitis.2022Scandinavian journal of immunology
  17. The clinical and laboratory features associated with cancer in patients with primary biliary cholangitis: a longitudinal survey-based study.2021Clinical rheumatology
  18. Clinical characteristics and prognosis of concomitant systemic lupus erythematosus and primary biliary cholangitis.2021Clinical rheumatology
  19. Changes of Serum IgG Glycosylation Patterns in Primary Biliary Cholangitis Patients.2021Frontiers in immunology
  20. CXCL12-CXCR4-Mediated Chemotaxis Supports Accumulation of Mucosal-Associated Invariant T Cells Into the Liver of Patients With PBC.2021Frontiers in immunology
  21. MicroRNA-34a Promotes EMT and Liver Fibrosis in Primary Biliary Cholangitis by Regulating TGF-β1/smad Pathway.2021Journal of immunology research
  22. Autoimmune enteropathy and primary biliary cholangitis after proctocolectomy for ulcerative colitis: A case report and review of the literature.2021World journal of gastroenterology
Chinese-language papers (not in the count)1
  1. [Recommendations for diagnosis and treatment of primary biliary cholangitis in China (2021)].2021Zhonghua nei ke za zhi
Earlier papers (2016–2020)7
  1. Role of cell autophagy in the generation of IgM and hepatic fibrosis in primary biliary cholangitis.2020Clinical rheumatology
  2. Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis.2020Frontiers in immunology
  3. [The effect of Cathepsin S in primary biliary cholangitis].2019Zhonghua yi xue za zhi
  4. Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: A case report.2018Medicine
  5. Cardiac involvement in patients with primary biliary cholangitis: A 14-year longitudinal survey-based study.2018PloS one
  6. Therapeutic advances for primary biliary cholangitis: the old and the new.2016European journal of gastroenterology & hepatology
  7. Association of IL12A Expression Quantitative Trait Loci (eQTL) With Primary Biliary Cirrhosis in a Chinese Han Population.2016Medicine
All its trials on ClinicalTrials.gov, any status5
  1. Clinical Research of Tapering UDCA in PBC Patients With a Complete ResponseRecruitingNCT04650243Lead sponsorPhase 4Start 2020-01
  2. Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary CirrhosisStatus unknownNCT01440309Lead (inferred)Phase 1Start 2011-11
  3. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary CholangitisRecruitingNCT05749822Study sitePhase 2/Phase 3Start 2023-02
  4. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08
  5. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary CholangitisActive, not recruitingNCT06174402Study sitePhase 2/Phase 3Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 3 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 3.0%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025

10 hospitals in Beijing for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07387549

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led 2 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 3.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

4 hospitals in Beijing for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

8 hospitals in Beijing for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Beijing for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Treatment progress of inherited epidermolysis bullosa.2025Expert opinion on biological therapy
Chinese-language papers (not in the count)1
  1. [Clinical Characteristics and Gene Mutations in 186 Cases of Kindler Syndrome].2022Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
Earlier papers (2016–2020)1
  1. Coexistence of acquired hemophilia A and epidermolysis bullosa acquisita: Two case reports and published work review.2017The Journal of dermatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led 10 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 31.2%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 0020232024: 1120242025: 442025

4 hospitals in Beijing for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology
Papers it led10
  1. Expert Consensus on the Diagnosis and Treatment of Hereditary Angioedema in China (2024 Edition).2026International archives of allergy and immunology
  2. Hereditary Angioedema (HAE) in China: Advancing Awareness, Access, Advocacy and Alliances From the Greater Bay Area to the Global HAE Community.2025Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  3. Study of Urinary Protein Biomarkers in Hereditary Angioedema.2025Journal of investigational allergology & clinical immunology
  4. Proactive identification of rare diseases: lessons from hereditary angioedema diagnosis using electronic medical records.2025Orphanet journal of rare diseases
  5. Elevated level of circulating VEGF in Chinese patients with hereditary angioedema and its correlation with disease status.2025Orphanet journal of rare diseases
  6. Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review.2024Orphanet journal of rare diseases
  7. Gut microbiome alterations in hereditary angioedema.2022Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  8. Long-term prophylaxis of hereditary angioedema with danazol.2022Chinese medical journal
  9. Mutation update of SERPING1 related to hereditary angioedema in the Chinese population.2022Hereditas
  10. Recurrent and acute abdominal pain as the main clinical manifestation in patients with hereditary angioedema.2021Allergy and asthma proceedings
Earlier papers (2016–2020)4
  1. Current status of the management of hereditary angioedema in China: a patient-based, cross-sectional survey.2020European journal of dermatology : EJD
  2. The natural course of hereditary angioedema in a Chinese cohort.2020Orphanet journal of rare diseases
  3. Risk factors for diagnostic delay in Chinese patients with hereditary angioedema.2019Allergy and asthma proceedings
  4. Health-related quality of life and its risk factors in Chinese hereditary angioedema patients.2019Orphanet journal of rare diseases
All its trials on ClinicalTrials.gov, any status2
  1. A Phase 2 in Adult Subjects With Hereditary AngioedemaActive, not recruitingNCT06846398Study sitePhase 2Start 2025-02
  2. A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)CompletedNCT05460325Study sitePhase 3Start 2022-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Majeed syndrome

Majeed 综合征

Led no English-language PubMed papers on Majeed syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Beijing for Majeed syndrome7 hospitals in China for Majeed syndrome

No open trial on Majeed syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Chinese-language papers (not in the count)1
  1. [Clinical analysis of 49 cases of non-inflammasome related conditions].2022Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

北京协和医院

Peking Union Medical College Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Peking Union Medical College Hospital; Peking Union Medical College Hospital (West Campus); Peking Union Medical College Hospital and Peking Union Medical College; Peking Union Medical College Hospital (Dongdan campus); Beijing Xiehe Hospital; PUMCH

Suggest a correctionDownload the data